{"recordsFiltered":50704,"recordsTotal":50704,"next":"http://fdaaa.trialstracker.net/api/trials/?format=json&length=300&start=50400","previous":"http://fdaaa.trialstracker.net/api/trials/?format=json&length=300&start=49800","results":[{"registry_id":"NCT04127578","publication_url":"https://clinicaltrials.gov/study/NCT04127578","title":"A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)","has_exemption":false,"start_date":"2020-01-03","completion_date":"2031-08-31","has_results":false,"results_due":false,"sponsor_name":"Prevail Therapeutics","sponsor_slug":"prevail-therapeutics","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04895709","publication_url":"https://clinicaltrials.gov/study/NCT04895709","title":"A Phase 1/2 Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors","has_exemption":false,"start_date":"2021-05-27","completion_date":"2031-08-31","has_results":false,"results_due":false,"sponsor_name":"Bristol-Myers Squibb","sponsor_slug":"bristol-myers-squibb","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04933721","publication_url":"https://clinicaltrials.gov/study/NCT04933721","title":"An Open-label Study to Provide Berotralstat Access to Subjects With Type 1 and 2 Hereditary Angioedema Who Were Previously Enrolled in Berotralstat Studies","has_exemption":false,"start_date":"2021-07-23","completion_date":"2031-08-31","has_results":false,"results_due":false,"sponsor_name":"BioCryst Pharmaceuticals","sponsor_slug":"biocryst-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06790784","publication_url":"https://clinicaltrials.gov/study/NCT06790784","title":"A Randomized Clinical Trial Evaluating Combination Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of Proliferative Diabetic Retinopathy","has_exemption":false,"start_date":"2025-08-04","completion_date":"2031-08-31","has_results":false,"results_due":false,"sponsor_name":"Jaeb Center for Health Research","sponsor_slug":"jaeb-center-for-health-research","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06441006","publication_url":"https://clinicaltrials.gov/study/NCT06441006","title":"Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis (PRISM-TB)","has_exemption":false,"start_date":"2025-10-03","completion_date":"2031-08-31","has_results":false,"results_due":false,"sponsor_name":"University of California, San Francisco","sponsor_slug":"university-of-california-san-francisco","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07322146","publication_url":"https://clinicaltrials.gov/study/NCT07322146","title":"Comparing Two Durations of Antibiotic Treatment for Children Hospitalized With Common Infections","has_exemption":false,"start_date":"2026-02-13","completion_date":"2031-08-31","has_results":false,"results_due":false,"sponsor_name":"University of California, San Francisco","sponsor_slug":"university-of-california-san-francisco","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07725380","publication_url":"https://clinicaltrials.gov/study/NCT07725380","title":"Open-Label, Cohort-Sequential Dose-Escalation and Dose-Confirmation Phase 1/2 Clinical Trial to Evaluate the Safety and Efficacy of Domatinostat in Combination With Sirolimus in Adolescents and Adults With Relapsed, Refractory Sarcoma and Osteosarcoma","has_exemption":false,"start_date":"2026-07-15","completion_date":"2031-08-31","has_results":false,"results_due":false,"sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","sponsor_slug":"h-lee-moffitt-cancer-center-and-research-institute","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07594015","publication_url":"https://clinicaltrials.gov/study/NCT07594015","title":"Phase 2 Open-Label Trial Investigating the Efficacy and Safety of Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy Maintenance","has_exemption":false,"start_date":"2026-08-06","completion_date":"2031-08-31","has_results":false,"results_due":false,"sponsor_name":"University of Miami","sponsor_slug":"university-of-miami","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07558265","publication_url":"https://clinicaltrials.gov/study/NCT07558265","title":"WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department","has_exemption":false,"start_date":"2026-08-18","completion_date":"2031-08-31","has_results":false,"results_due":false,"sponsor_name":"Ohio State University","sponsor_slug":"ohio-state-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT02448173","publication_url":"https://clinicaltrials.gov/study/NCT02448173","title":"A Randomized Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer","has_exemption":false,"start_date":"2026-08-31","completion_date":"2031-08-31","has_results":false,"results_due":false,"sponsor_name":"Vaccinogen Inc","sponsor_slug":"vaccinogen-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07325175","publication_url":"https://clinicaltrials.gov/study/NCT07325175","title":"Quantifying Motor Network Dynamics to Predict and Enhance Outcomes in Pediatric Dystonia","has_exemption":false,"start_date":"2026-09-01","completion_date":"2031-08-31","has_results":false,"results_due":false,"sponsor_name":"Children's Hospital Medical Center, Cincinnati","sponsor_slug":"childrens-hospital-medical-center-cincinnati","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07634562","publication_url":"https://clinicaltrials.gov/study/NCT07634562","title":"A Phase 1-2 Prospective Study to Evaluate the Safety and Feasibility of Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) in Liver Transplantation Recipients to Induce Immune Tolerance","has_exemption":false,"start_date":"2026-09-01","completion_date":"2031-08-31","has_results":false,"results_due":false,"sponsor_name":"Stanford University","sponsor_slug":"stanford-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06639607","publication_url":"https://clinicaltrials.gov/study/NCT06639607","title":"Phase 1/2 Trial of PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma (PRiME II)","has_exemption":false,"start_date":"2026-09-30","completion_date":"2031-08-31","has_results":false,"results_due":false,"sponsor_name":"Washington University School of Medicine","sponsor_slug":"washington-university-school-of-medicine","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07605923","publication_url":"https://clinicaltrials.gov/study/NCT07605923","title":"Methylprednisolone Addition to Multimodal Pain Regimens After Anterior Cruciate Ligament Reconstruction","has_exemption":false,"start_date":"2026-09-30","completion_date":"2031-08-31","has_results":false,"results_due":false,"sponsor_name":"University of Alabama at Birmingham","sponsor_slug":"university-of-alabama-at-birmingham","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07735533","publication_url":"https://clinicaltrials.gov/study/NCT07735533","title":"A Phase 1/2, Open-label, Multicenter Study of UB-VV400 With Rapamycin in Relapsed or Refractory B-cell Malignancies","has_exemption":false,"start_date":"2026-09-30","completion_date":"2031-08-31","has_results":false,"results_due":false,"sponsor_name":"Umoja Biopharma","sponsor_slug":"umoja-biopharma","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07743164","publication_url":"https://clinicaltrials.gov/study/NCT07743164","title":"A Phase 3, Open-Label, Multicenter, Randomized Study of Raludotatug Deruxtecan (MK-5909, R-DXd) With or Without Bevacizumab Versus Standard-of-Care Platinum-Based Doublet Chemotherapy With or Without Bevacizumab in Participants With Advanced Platinum-Sensitive High-Grade Serous or High-Grade Endometrioid Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Have Progressed During First-Line PARPi Maintenance (ENGOT-ov107 / GOG-3142 / REJOICE-Ovarian05)","has_exemption":false,"start_date":"2026-10-07","completion_date":"2031-08-31","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05155033","publication_url":"https://clinicaltrials.gov/study/NCT05155033","title":"Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma","has_exemption":false,"start_date":"2022-08-18","completion_date":"2031-09-01","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06188741","publication_url":"https://clinicaltrials.gov/study/NCT06188741","title":"Phase 2 Trial of Selumetinib for the Prevention of Plexiform Neurofibroma Growth and Morbidity in Neurofibromatosis Type 1","has_exemption":false,"start_date":"2025-08-27","completion_date":"2031-09-01","has_results":false,"results_due":false,"sponsor_name":"University of Alabama at Birmingham","sponsor_slug":"university-of-alabama-at-birmingham","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07840287","publication_url":"https://clinicaltrials.gov/study/NCT07840287","title":"A Phase 3, Single-Arm, Open-Label, Long-Term Extension Study To Evaluate The Safety And Efficacy Of Enpatoran In Participants With Active Cutaneous Manifestations Of Lupus Erythematosus With Or Without Systemic Disease Receiving Standard Of Care [Elowen-LTE]","has_exemption":false,"start_date":"2026-10-15","completion_date":"2031-09-01","has_results":false,"results_due":false,"sponsor_name":"EMD Serono Research & Development Institute, Inc.","sponsor_slug":"emd-serono-research-development-institute-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07392580","publication_url":"https://clinicaltrials.gov/study/NCT07392580","title":"A Single-Arm, Open-Label Study of Intralesional Treatment of Laryngeal Squamous Cell Carcinoma With Cisplatin","has_exemption":false,"start_date":"2026-12-01","completion_date":"2031-09-01","has_results":false,"results_due":false,"sponsor_name":"University of Miami","sponsor_slug":"university-of-miami","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07649291","publication_url":"https://clinicaltrials.gov/study/NCT07649291","title":"Duloxetine Plus Exercise to Improve Physical Function in Veterans With Knee Osteoarthritis, Pain, and Psychological Comorbidity","has_exemption":false,"start_date":"2027-03-01","completion_date":"2031-09-01","has_results":false,"results_due":false,"sponsor_name":"VA Office of Research and Development","sponsor_slug":"va-office-of-research-and-development","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06833073","publication_url":"https://clinicaltrials.gov/study/NCT06833073","title":"A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011)","has_exemption":false,"start_date":"2025-03-11","completion_date":"2031-09-03","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04929028","publication_url":"https://clinicaltrials.gov/study/NCT04929028","title":"Risk-Adapted Therapy for HIV-Associated Anal Cancer","has_exemption":false,"start_date":"2022-08-09","completion_date":"2031-09-15","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07498335","publication_url":"https://clinicaltrials.gov/study/NCT07498335","title":"A Single-arm, Multicenter, Phase III Study to Assess Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients of 2 to <18 Years of Age With Primary Immunoglobulin A Nephropathy (IgAN)","has_exemption":false,"start_date":"2026-08-06","completion_date":"2031-09-15","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT02919592","publication_url":"https://clinicaltrials.gov/study/NCT02919592","title":"MemoryShape® and MemoryGel® Breast Implants Post Approval New Enrollment Study (\"Glow Study\")","has_exemption":false,"start_date":"2016-09-01","completion_date":"2031-09-16","has_results":false,"results_due":false,"sponsor_name":"Mentor Worldwide, LLC","sponsor_slug":"mentor-worldwide-llc","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT05627362","publication_url":"https://clinicaltrials.gov/study/NCT05627362","title":"A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC).","has_exemption":false,"start_date":"2022-12-29","completion_date":"2031-09-23","has_results":false,"results_due":false,"sponsor_name":"Ipsen","sponsor_slug":"ipsen","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07851220","publication_url":"https://clinicaltrials.gov/study/NCT07851220","title":"A Phase 3 Randomized, Open-Label Multicenter Study to Evaluate Efficacy and Safety of Inebilizumab in Adult Participants With Primary Membranous Nephropathy (PMN)","has_exemption":false,"start_date":"2026-10-01","completion_date":"2031-09-27","has_results":false,"results_due":false,"sponsor_name":"Amgen","sponsor_slug":"amgen","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04245839","publication_url":"https://clinicaltrials.gov/study/NCT04245839","title":"A Phase 2, Open-label, Single Arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)","has_exemption":false,"start_date":"2020-07-14","completion_date":"2031-09-30","has_results":false,"results_due":false,"sponsor_name":"Celgene","sponsor_slug":"celgene","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05524883","publication_url":"https://clinicaltrials.gov/study/NCT05524883","title":"A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-251 Administered to Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping","has_exemption":false,"start_date":"2022-08-12","completion_date":"2031-09-30","has_results":false,"results_due":false,"sponsor_name":"Dyne Therapeutics","sponsor_slug":"dyne-therapeutics","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07153796","publication_url":"https://clinicaltrials.gov/study/NCT07153796","title":"A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia","has_exemption":false,"start_date":"2026-01-30","completion_date":"2031-09-30","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07283679","publication_url":"https://clinicaltrials.gov/study/NCT07283679","title":"Phase I/II Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma","has_exemption":false,"start_date":"2026-02-24","completion_date":"2031-09-30","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07680153","publication_url":"https://clinicaltrials.gov/study/NCT07680153","title":"Neuromodulation of Mood Switch Circuitry in Bipolar Disorder","has_exemption":false,"start_date":"2026-08-03","completion_date":"2031-09-30","has_results":false,"results_due":false,"sponsor_name":"Weill Medical College of Cornell University","sponsor_slug":"weill-medical-college-of-cornell-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07744919","publication_url":"https://clinicaltrials.gov/study/NCT07744919","title":"A Phase 2 Study of Emapalumab for Prevention of Liver Failure in Pediatric Indeterminate Severe Hepatitis Associated With T-Cell Activation: Severe Hepatitis Intervention With Emapalumab for Liver Disease","has_exemption":false,"start_date":"2026-09-01","completion_date":"2031-09-30","has_results":false,"results_due":false,"sponsor_name":"Children's Healthcare of Atlanta","sponsor_slug":"childrens-healthcare-of-atlanta","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07321899","publication_url":"https://clinicaltrials.gov/study/NCT07321899","title":"Transcatheter Tricuspid Valve Replacement Using the Medtronic Intrepid™ TTVR System in Patients With Severe Symptomatic Tricuspid Regurgitation - PATHFINDER","has_exemption":false,"start_date":"2026-09-11","completion_date":"2031-09-30","has_results":false,"results_due":false,"sponsor_name":"Medtronic Cardiovascular","sponsor_slug":"medtronic-cardiovascular","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07710534","publication_url":"https://clinicaltrials.gov/study/NCT07710534","title":"Metronomic Decitabine-Cedazuridine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia R/R AML), High Risk Myelodysplastic Syndrome (HR-MDS), and High-Risk Myeloproliferative Neoplasms (HR/AP MPN)","has_exemption":false,"start_date":"2026-09-16","completion_date":"2031-09-30","has_results":false,"results_due":false,"sponsor_name":"Virginia Commonwealth University","sponsor_slug":"virginia-commonwealth-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07468916","publication_url":"https://clinicaltrials.gov/study/NCT07468916","title":"Ropeginterferon Alfa-2b for MDS/MPN Overlap Syndromes, Including CMML and MDS/MPN-RS-T","has_exemption":false,"start_date":"2026-09-29","completion_date":"2031-09-30","has_results":false,"results_due":false,"sponsor_name":"Jonsson Comprehensive Cancer Center","sponsor_slug":"jonsson-comprehensive-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07660783","publication_url":"https://clinicaltrials.gov/study/NCT07660783","title":"A Phase II Prospective Study Evaluating Selective Depletion of CD45RA+ (Naïve) T Cells (TND) From Peripheral Blood Stem Cell (PBSC) Grafts for Prevention of Graft Versus Host Disease (GVHD) in Non-Malignant Diseases (NMDs)","has_exemption":false,"start_date":"2026-09-30","completion_date":"2031-09-30","has_results":false,"results_due":false,"sponsor_name":"Fred Hutchinson Cancer Center","sponsor_slug":"fred-hutchinson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07744191","publication_url":"https://clinicaltrials.gov/study/NCT07744191","title":"A Randomized, Double-blind, Placebo-controlled Crossover Trial of Antiplatelet Therapies in Psoriasis","has_exemption":false,"start_date":"2026-09-30","completion_date":"2031-09-30","has_results":false,"results_due":false,"sponsor_name":"NYU Langone Health","sponsor_slug":"nyu-langone-health","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06222268","publication_url":"https://clinicaltrials.gov/study/NCT06222268","title":"Wayne State Warriors Marijuana Clinical Research Program: Cannabinoid Adjunct to Prolonged Exposure & Recovery","has_exemption":false,"start_date":"2026-09-30","completion_date":"2031-09-30","has_results":false,"results_due":false,"sponsor_name":"Leslie Lundahl","sponsor_slug":"leslie-lundahl","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07785609","publication_url":"https://clinicaltrials.gov/study/NCT07785609","title":"Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of MK-2010 in Combination With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Advanced Solid Tumors","has_exemption":false,"start_date":"2026-10-07","completion_date":"2031-09-30","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07528326","publication_url":"https://clinicaltrials.gov/study/NCT07528326","title":"TRiCares Topaz Transcatheter Tricuspid Heart Valve Replacement System IDE Pivotal Study","has_exemption":false,"start_date":"2026-10-31","completion_date":"2031-09-30","has_results":false,"results_due":false,"sponsor_name":"TRiCares","sponsor_slug":"tricares","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07164469","publication_url":"https://clinicaltrials.gov/study/NCT07164469","title":"Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma","has_exemption":false,"start_date":"2026-12-28","completion_date":"2031-09-30","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07178912","publication_url":"https://clinicaltrials.gov/study/NCT07178912","title":"Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)","has_exemption":false,"start_date":"2027-01-27","completion_date":"2031-09-30","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07742553","publication_url":"https://clinicaltrials.gov/study/NCT07742553","title":"A Multisite, Double-blind, Randomized Controlled Trial Comparing Body Composition, Muscle, and Bone Changes to TestosteRone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial","has_exemption":false,"start_date":"2027-10-01","completion_date":"2031-09-30","has_results":false,"results_due":false,"sponsor_name":"VA Office of Research and Development","sponsor_slug":"va-office-of-research-and-development","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06863272","publication_url":"https://clinicaltrials.gov/study/NCT06863272","title":"MK-2400-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)","has_exemption":false,"start_date":"2025-07-03","completion_date":"2031-10-01","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07043738","publication_url":"https://clinicaltrials.gov/study/NCT07043738","title":"Imaging- vs. Scalp-Targeted Accelerated TMS for Depression: The Number Needed to Scan Trial","has_exemption":false,"start_date":"2026-10-01","completion_date":"2031-10-01","has_results":false,"results_due":false,"sponsor_name":"Brigham and Women's Hospital","sponsor_slug":"brigham-and-womens-hospital","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07214896","publication_url":"https://clinicaltrials.gov/study/NCT07214896","title":"HEALTH: Humanoid Evaluation and Learning Trial in Coalition-Aligned Healthcare Settings","has_exemption":false,"start_date":"2025-10-06","completion_date":"2031-10-06","has_results":false,"results_due":false,"sponsor_name":"Truway Health, Inc.","sponsor_slug":"truway-health-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06934967","publication_url":"https://clinicaltrials.gov/study/NCT06934967","title":"An Open-label, Single-arm, Multicenter, Phase 3 Study to Assess Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric PNH Patients 2 to <18 Years of Age","has_exemption":false,"start_date":"2025-10-28","completion_date":"2031-10-14","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07361510","publication_url":"https://clinicaltrials.gov/study/NCT07361510","title":"ROSETTA Lung-202: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With PD-L1 ≥ 50%.","has_exemption":false,"start_date":"2026-03-12","completion_date":"2031-10-14","has_results":false,"results_due":false,"sponsor_name":"Bristol-Myers Squibb","sponsor_slug":"bristol-myers-squibb","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05624996","publication_url":"https://clinicaltrials.gov/study/NCT05624996","title":"Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer","has_exemption":false,"start_date":"2023-07-12","completion_date":"2031-10-15","has_results":false,"results_due":false,"sponsor_name":"NRG Oncology","sponsor_slug":"nrg-oncology","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07834762","publication_url":"https://clinicaltrials.gov/study/NCT07834762","title":"Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression: A Home-Based Randomized Sham-Controlled Trial and Mechanistic Exploration","has_exemption":false,"start_date":"2026-10-15","completion_date":"2031-10-15","has_results":false,"results_due":false,"sponsor_name":"University of California, San Diego","sponsor_slug":"university-of-california-san-diego","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07136012","publication_url":"https://clinicaltrials.gov/study/NCT07136012","title":"A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)","has_exemption":false,"start_date":"2025-08-22","completion_date":"2031-10-20","has_results":false,"results_due":false,"sponsor_name":"Amgen","sponsor_slug":"amgen","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07660094","publication_url":"https://clinicaltrials.gov/study/NCT07660094","title":"A Phase 3, Multicenter, Randomized, Controlled, Open-Label Clinical Trial of Aglatimagene Besadenovec (CAN-2409) Plus Prodrug and Pembrolizumab Versus Docetaxel for Stage IV Non-Squamous Non-Small Cell Lung Cancer Progressing on Pembrolizumab-based Treatment","has_exemption":false,"start_date":"2026-06-15","completion_date":"2031-10-22","has_results":false,"results_due":false,"sponsor_name":"Candel Therapeutics, Inc.","sponsor_slug":"candel-therapeutics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07013487","publication_url":"https://clinicaltrials.gov/study/NCT07013487","title":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Immunogenicity, and Efficacy of V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age","has_exemption":false,"start_date":"2025-06-11","completion_date":"2031-10-24","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07049926","publication_url":"https://clinicaltrials.gov/study/NCT07049926","title":"A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (KEYMAKER-U03): Substudy 03C in Participants With Recurrent Disease During or After Anti-PD-(L)1 Adjuvant Therapy","has_exemption":false,"start_date":"2025-07-20","completion_date":"2031-10-26","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07216703","publication_url":"https://clinicaltrials.gov/study/NCT07216703","title":"A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as Firstline Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse-036/GOG-3123/ENGOT-cx22)","has_exemption":false,"start_date":"2026-01-19","completion_date":"2031-10-29","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07665437","publication_url":"https://clinicaltrials.gov/study/NCT07665437","title":"A Double-blind, Double-dummy, Parallel Group, Multicenter Phase 3 Extension Study Evaluating the Long-term Safety and Efficacy of 2 Doses of Remibrutinib in Adult Participants With Moderate to Severe Hidradenitis Suppurativa","has_exemption":false,"start_date":"2026-07-10","completion_date":"2031-10-29","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05951179","publication_url":"https://clinicaltrials.gov/study/NCT05951179","title":"A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Intravesical Instillation of TARA-002 in Adults With High-Grade Non-Muscle Invasive Bladder Cancer","has_exemption":false,"start_date":"2023-09-15","completion_date":"2031-10-31","has_results":false,"results_due":false,"sponsor_name":"Protara Therapeutics","sponsor_slug":"protara-therapeutics","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06236438","publication_url":"https://clinicaltrials.gov/study/NCT06236438","title":"A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","has_exemption":false,"start_date":"2024-04-10","completion_date":"2031-10-31","has_results":false,"results_due":false,"sponsor_name":"AbbVie","sponsor_slug":"abbvie","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06372964","publication_url":"https://clinicaltrials.gov/study/NCT06372964","title":"A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Lumateperone for the Treatment of Major Depressive Episodes (MDEs) Associated With Bipolar I or Bipolar II Disorder (Bipolar Depression) in Pediatric Patients Aged 10 to 17 Years","has_exemption":false,"start_date":"2024-05-14","completion_date":"2031-10-31","has_results":false,"results_due":false,"sponsor_name":"Intra-Cellular Therapies, Inc.","sponsor_slug":"intra-cellular-therapies-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06013423","publication_url":"https://clinicaltrials.gov/study/NCT06013423","title":"Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults and Pediatrics","has_exemption":false,"start_date":"2024-07-23","completion_date":"2031-10-31","has_results":false,"results_due":false,"sponsor_name":"Fred Hutchinson Cancer Center","sponsor_slug":"fred-hutchinson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06898450","publication_url":"https://clinicaltrials.gov/study/NCT06898450","title":"A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of NDI-219216 in Patients With Advanced Solid Tumors With/Without Microsatellite Instability and/or Deficient Mismatch Repair","has_exemption":false,"start_date":"2025-03-31","completion_date":"2031-10-31","has_results":false,"results_due":false,"sponsor_name":"Nimbus Wadjet, Inc.","sponsor_slug":"nimbus-wadjet-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06563895","publication_url":"https://clinicaltrials.gov/study/NCT06563895","title":"A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)","has_exemption":false,"start_date":"2025-05-12","completion_date":"2031-10-31","has_results":false,"results_due":false,"sponsor_name":"Eidos Therapeutics, a BridgeBio company","sponsor_slug":"eidos-therapeutics-a-bridgebio-company","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07110844","publication_url":"https://clinicaltrials.gov/study/NCT07110844","title":"A Phase 2 Clinical Trial of Teclistamab and Daratumumab in Previously Untreated AL Amyloidosis","has_exemption":false,"start_date":"2025-11-07","completion_date":"2031-10-31","has_results":false,"results_due":false,"sponsor_name":"Rajshekhar Chakraborty, MD","sponsor_slug":"rajshekhar-chakraborty-md","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07697456","publication_url":"https://clinicaltrials.gov/study/NCT07697456","title":"A Phase 2 Platform Basket Study Evaluating Advanced Therapies in Subjects With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis","has_exemption":false,"start_date":"2026-07-31","completion_date":"2031-10-31","has_results":false,"results_due":false,"sponsor_name":"AbbVie","sponsor_slug":"abbvie","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07689175","publication_url":"https://clinicaltrials.gov/study/NCT07689175","title":"Phase 2 Trial of Adaptive Dosing of Immune Checkpoint Inhibitors for Unresectable Child Pugh B Hepatocellular Carcinoma","has_exemption":false,"start_date":"2026-08-21","completion_date":"2031-10-31","has_results":false,"results_due":false,"sponsor_name":"University of Texas Southwestern Medical Center","sponsor_slug":"university-of-texas-southwestern-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07628101","publication_url":"https://clinicaltrials.gov/study/NCT07628101","title":"A Prospective Multi-Center, Single Arm, Open Label, Pivotal Clinical Study Designed to Assess the Safety, Performance, and Efficacy of the CardiaZn Stent in the Treatment of Pediatric Aortic Coarctation and Pulmonary Artery Stenosis","has_exemption":false,"start_date":"2026-10-31","completion_date":"2031-10-31","has_results":false,"results_due":false,"sponsor_name":"PediaStent LLC","sponsor_slug":"pediastent-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07835919","publication_url":"https://clinicaltrials.gov/study/NCT07835919","title":"Kids Injury Detection Study (KIDS-STAT) Using the i-STAT: Point of Care TBI Biomarker Testing","has_exemption":false,"start_date":"2026-10-31","completion_date":"2031-10-31","has_results":false,"results_due":false,"sponsor_name":"Children's Healthcare of Atlanta","sponsor_slug":"childrens-healthcare-of-atlanta","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03729817","publication_url":"https://clinicaltrials.gov/study/NCT03729817","title":"VERiTAS-2 REFRESH ICAS (REstoring Flow by REvascularization With Submaximal Angioplasty in Hemodynamic IntraCranial Atherosclerotic Stenosis)","has_exemption":false,"start_date":"2027-10-31","completion_date":"2031-10-31","has_results":false,"results_due":false,"sponsor_name":"Case Western Reserve University","sponsor_slug":"case-western-reserve-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07069595","publication_url":"https://clinicaltrials.gov/study/NCT07069595","title":"PREDICT-RD: Postoperative Molecular Residual Disease by ctDNA Surveillance in TNBC With Residual Disease","has_exemption":false,"start_date":"2026-02-26","completion_date":"2031-11-01","has_results":false,"results_due":false,"sponsor_name":"UNC Lineberger Comprehensive Cancer Center","sponsor_slug":"unc-lineberger-comprehensive-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07582172","publication_url":"https://clinicaltrials.gov/study/NCT07582172","title":"Phase 2 Trial of Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplantation (PBSC-HCT) From a Match Donor With Fludarabine and Melphalan in Older Patients With Refractory Acute Myeloid Leukemia and MDS","has_exemption":false,"start_date":"2026-11-05","completion_date":"2031-11-05","has_results":false,"results_due":false,"sponsor_name":"City of Hope Medical Center","sponsor_slug":"city-of-hope-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05253131","publication_url":"https://clinicaltrials.gov/study/NCT05253131","title":"Phase 1/2 Trial of the MEK Inhibitor Selumetinib and Bromodomain Inhibitor ZEN-3694 With Durvalumab (MEDI4736), a PD-L1 Antibody for Sarcomas Including Malignant Peripheral Nerve Sheath Tumors","has_exemption":false,"start_date":"2026-08-04","completion_date":"2031-11-15","has_results":false,"results_due":false,"sponsor_name":"University of Alabama at Birmingham","sponsor_slug":"university-of-alabama-at-birmingham","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07829783","publication_url":"https://clinicaltrials.gov/study/NCT07829783","title":"A Phase 3 Study Evaluating Sacituzumab Tirumotecan Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) as Induction Therapy, Followed by Local Therapy With Chemoradiation and MK-3475A Consolidation Versus Local Therapy With Chemoradiation in Participants With MIBC Who Elect Bladder Preservation","has_exemption":false,"start_date":"2026-10-20","completion_date":"2031-11-17","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07214467","publication_url":"https://clinicaltrials.gov/study/NCT07214467","title":"Individualized Adaptive Deep Brain Stimulation in Opioid Use Disorder","has_exemption":false,"start_date":"2025-10-24","completion_date":"2031-11-22","has_results":false,"results_due":false,"sponsor_name":"University of California, San Francisco","sponsor_slug":"university-of-california-san-francisco","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06549595","publication_url":"https://clinicaltrials.gov/study/NCT06549595","title":"A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 Plus Rituximab Versus Chemotherapy Plus Rituximab in Previously Untreated Participants With Follicular Lymphoma (SOUNDTRACK-F1)","has_exemption":false,"start_date":"2024-08-07","completion_date":"2031-11-26","has_results":false,"results_due":false,"sponsor_name":"AstraZeneca","sponsor_slug":"astrazeneca","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07753824","publication_url":"https://clinicaltrials.gov/study/NCT07753824","title":"A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)","has_exemption":false,"start_date":"2027-01-16","completion_date":"2031-11-28","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05461170","publication_url":"https://clinicaltrials.gov/study/NCT05461170","title":"A Phase 2 Study to Evaluate Efficacy, Safety and Tolerability of VIR-2218 and VIR-3434 in Participants With Chronic Hepatitis D Virus Infection (SOLSTICE)","has_exemption":false,"start_date":"2022-09-17","completion_date":"2031-11-30","has_results":false,"results_due":false,"sponsor_name":"Vir Biotechnology, Inc.","sponsor_slug":"vir-biotechnology-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06969430","publication_url":"https://clinicaltrials.gov/study/NCT06969430","title":"A Phase 1/2, First-in-human, Multicenter, Open-label Trial Evaluating the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)","has_exemption":false,"start_date":"2025-05-30","completion_date":"2031-11-30","has_results":false,"results_due":false,"sponsor_name":"Debiopharm International SA","sponsor_slug":"debiopharm-international-sa","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07007312","publication_url":"https://clinicaltrials.gov/study/NCT07007312","title":"Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination With Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients With Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia","has_exemption":false,"start_date":"2025-09-26","completion_date":"2031-11-30","has_results":false,"results_due":false,"sponsor_name":"Kura Oncology, Inc.","sponsor_slug":"kura-oncology-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07285239","publication_url":"https://clinicaltrials.gov/study/NCT07285239","title":"Randomized Phase 3 Trial of Belantamab Mafodotin or Daratumumab in Combination With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma","has_exemption":false,"start_date":"2026-09-30","completion_date":"2031-11-30","has_results":false,"results_due":false,"sponsor_name":"PrECOG, LLC.","sponsor_slug":"precog-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07717736","publication_url":"https://clinicaltrials.gov/study/NCT07717736","title":"Phase 4 Master Protocol for Patients Prescribed Prademagene Zamikeracel for the Treatment of Wounds","has_exemption":false,"start_date":"2026-11-30","completion_date":"2031-11-30","has_results":false,"results_due":false,"sponsor_name":"Abeona Therapeutics, Inc","sponsor_slug":"abeona-therapeutics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07808112","publication_url":"https://clinicaltrials.gov/study/NCT07808112","title":"Phase II Open-Label, Randomized-Controlled Trial of CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell Transplantation","has_exemption":false,"start_date":"2026-11-30","completion_date":"2031-11-30","has_results":false,"results_due":false,"sponsor_name":"Medical College of Wisconsin","sponsor_slug":"medical-college-of-wisconsin","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07735208","publication_url":"https://clinicaltrials.gov/study/NCT07735208","title":"Geriatric Assessment-Guided Treatment Selection in Older Adults With Acute Myeloid Leukemia (The ALIGN-AML Trial)","has_exemption":false,"start_date":"2026-12-01","completion_date":"2031-11-30","has_results":false,"results_due":false,"sponsor_name":"University of Rochester","sponsor_slug":"university-of-rochester","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07783555","publication_url":"https://clinicaltrials.gov/study/NCT07783555","title":"Varenicline as a Treatment for Cannabis Use Disorder","has_exemption":false,"start_date":"2026-12-01","completion_date":"2031-11-30","has_results":false,"results_due":false,"sponsor_name":"Medical University of South Carolina","sponsor_slug":"medical-university-of-south-carolina","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07868679","publication_url":"https://clinicaltrials.gov/study/NCT07868679","title":"THiamine for Recovery In Vulnerable Early-life Infections","has_exemption":false,"start_date":"2026-12-01","completion_date":"2031-11-30","has_results":false,"results_due":false,"sponsor_name":"Milton S. Hershey Medical Center","sponsor_slug":"milton-s-hershey-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06813014","publication_url":"https://clinicaltrials.gov/study/NCT06813014","title":"Sitagliptin&#39;s Effects on Glucose-stimulated Insulin Secretion and Oral Glucose","has_exemption":false,"start_date":"2026-12-31","completion_date":"2031-11-30","has_results":false,"results_due":false,"sponsor_name":"University of Maryland, Baltimore","sponsor_slug":"university-of-maryland-baltimore","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04007276","publication_url":"https://clinicaltrials.gov/study/NCT04007276","title":"The Effect of Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients Using Brimonidine 0.2%, 0.15%, or 0.1%","has_exemption":false,"start_date":"2027-11-30","completion_date":"2031-11-30","has_results":false,"results_due":false,"sponsor_name":"Tulane University","sponsor_slug":"tulane-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05145010","publication_url":"https://clinicaltrials.gov/study/NCT05145010","title":"Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL OLE","has_exemption":false,"start_date":"2021-12-06","completion_date":"2031-12-01","has_results":false,"results_due":false,"sponsor_name":"QED Therapeutics, a BridgeBio company","sponsor_slug":"qed-therapeutics-a-bridgebio-company","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06851754","publication_url":"https://clinicaltrials.gov/study/NCT06851754","title":"Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency","has_exemption":false,"start_date":"2025-07-17","completion_date":"2031-12-01","has_results":false,"results_due":false,"sponsor_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","sponsor_slug":"eunice-kennedy-shriver-national-institute-of-child-health-and-human-development-nichd","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07225972","publication_url":"https://clinicaltrials.gov/study/NCT07225972","title":"An Open-Label Prospective Randomized Trial of Family Donor-Derived ADV or CMV CTLs Plus Standard of Care (SOC) vs SOC Alone in Children, Adolescents and Young Adults Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) With Refractory ADV or CMV Infection/Viremia","has_exemption":false,"start_date":"2026-09-01","completion_date":"2031-12-01","has_results":false,"results_due":false,"sponsor_name":"New York Medical College","sponsor_slug":"new-york-medical-college","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05145309","publication_url":"https://clinicaltrials.gov/study/NCT05145309","title":"Value of Potassium Magnesium Citrate in Preventing and Treating Hypertension in African Americans","has_exemption":false,"start_date":"2026-11-15","completion_date":"2031-12-01","has_results":false,"results_due":false,"sponsor_name":"University of Texas Southwestern Medical Center","sponsor_slug":"university-of-texas-southwestern-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07587593","publication_url":"https://clinicaltrials.gov/study/NCT07587593","title":"Comparative Effectiveness of Interventions to Prevent Infections and Other Complications Arising From Central Venous Access Devices: the IVCare Adaptive Platform Trial.","has_exemption":false,"start_date":"2026-12-01","completion_date":"2031-12-01","has_results":false,"results_due":false,"sponsor_name":"The University of Queensland","sponsor_slug":"the-university-of-queensland","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07720180","publication_url":"https://clinicaltrials.gov/study/NCT07720180","title":"OVAFIT-TIL: A Phase Ib Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab in Recurrent Ovarian Cancer","has_exemption":false,"start_date":"2026-12-01","completion_date":"2031-12-01","has_results":false,"results_due":false,"sponsor_name":"Medical University of South Carolina","sponsor_slug":"medical-university-of-south-carolina","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07389239","publication_url":"https://clinicaltrials.gov/study/NCT07389239","title":"A Phase I/IIA Study Evaluating the Safety and Efficacy of NY-ESO-1TCR/dnTGFBRII Engineered T Cells in Combination With Decitabine in Subjects With Recurrent or Treatment Refractory Ovarian Cancer and Other Advanced Malignancies","has_exemption":false,"start_date":"2026-09-09","completion_date":"2031-12-10","has_results":false,"results_due":false,"sponsor_name":"University of Chicago","sponsor_slug":"university-of-chicago","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06663332","publication_url":"https://clinicaltrials.gov/study/NCT06663332","title":"CNTO1959ISD3001: A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study to Evaluate the Safety of Guselkumab in Pediatric Participants With Crohn's Disease, Ulcerative Colitis, or Juvenile Psoriatic Arthritis","has_exemption":false,"start_date":"2024-10-29","completion_date":"2031-12-12","has_results":false,"results_due":false,"sponsor_name":"Janssen Research & Development, LLC","sponsor_slug":"janssen-research-development-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT02128906","publication_url":"https://clinicaltrials.gov/study/NCT02128906","title":"A Randomized, Phase II Study of Definitive Radiotherapy With Concurrent Cisplatin vs. Docetaxel-cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma: an ERCC1 Biomarker Enrichment and Interaction Design","has_exemption":false,"start_date":"2013-12-23","completion_date":"2031-12-16","has_results":false,"results_due":false,"sponsor_name":"Christopher Wilke","sponsor_slug":"christopher-wilke","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT07730814","publication_url":"https://clinicaltrials.gov/study/NCT07730814","title":"Comparative Effectiveness of Available Treatments for Sinus and Ear Infections in Children (Acute Otitis Media)","has_exemption":false,"start_date":"2026-10-01","completion_date":"2031-12-18","has_results":false,"results_due":false,"sponsor_name":"Nader Shaikh","sponsor_slug":"nader-shaikh","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07732699","publication_url":"https://clinicaltrials.gov/study/NCT07732699","title":"Comparative Effectiveness of Available Treatments for Sinus and Ear Infections in Children (Acute Sinusitis)","has_exemption":false,"start_date":"2026-10-01","completion_date":"2031-12-18","has_results":false,"results_due":false,"sponsor_name":"Nader Shaikh","sponsor_slug":"nader-shaikh","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT02316379","publication_url":"https://clinicaltrials.gov/study/NCT02316379","title":"Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration","has_exemption":false,"start_date":"2015-02-28","completion_date":"2031-12-24","has_results":false,"results_due":false,"sponsor_name":"Children's Hospital Medical Center, Cincinnati","sponsor_slug":"childrens-hospital-medical-center-cincinnati","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT06632444","publication_url":"https://clinicaltrials.gov/study/NCT06632444","title":"A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase III Trial Evaluating Long-term Efficacy and Safety of Survodutide Weekly Injections in Adult Participants With Noncirrhotic Non-alcoholic Steatohepatitis/Metabolic Dysfunction-associated Steatohepatitis (NASH/MASH) and (F2) - (F3) Stage of Liver Fibrosis","has_exemption":false,"start_date":"2024-10-14","completion_date":"2031-12-27","has_results":false,"results_due":false,"sponsor_name":"Boehringer Ingelheim","sponsor_slug":"boehringer-ingelheim","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04580420","publication_url":"https://clinicaltrials.gov/study/NCT04580420","title":"A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 and Severe Renal Impairment, With or Without Dialysis","has_exemption":false,"start_date":"2021-04-15","completion_date":"2031-12-30","has_results":false,"results_due":false,"sponsor_name":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","sponsor_slug":"dicerna-pharmaceuticals-inc-a-novo-nordisk-company","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06620302","publication_url":"https://clinicaltrials.gov/study/NCT06620302","title":"DT2216 in Combination With Irinotecan for Children, Adolescents and Young Adults With Relapsed or Refractory Solid Tumors: A Phase I Study With Phase II Feasibility Cohort for Fibrolamellar Carcinoma","has_exemption":false,"start_date":"2025-06-12","completion_date":"2031-12-30","has_results":false,"results_due":false,"sponsor_name":"Children's Oncology Group","sponsor_slug":"childrens-oncology-group","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07680790","publication_url":"https://clinicaltrials.gov/study/NCT07680790","title":"A Phase III, Randomized, Open-label Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy as First-Line Therapy in Patients With EGFR-Mutant Locally Advanced or Metastatic Non-small Cell Lung Cancer","has_exemption":false,"start_date":"2026-09-08","completion_date":"2031-12-30","has_results":false,"results_due":false,"sponsor_name":"Bristol-Myers Squibb","sponsor_slug":"bristol-myers-squibb","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07223190","publication_url":"https://clinicaltrials.gov/study/NCT07223190","title":"A Phase 3, Open-label, Randomized, Controlled Trial of Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukaemia","has_exemption":false,"start_date":"2028-06-30","completion_date":"2031-12-30","has_results":false,"results_due":false,"sponsor_name":"Amgen","sponsor_slug":"amgen","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT01524211","publication_url":"https://clinicaltrials.gov/study/NCT01524211","title":"Evaluation of Branch Endografts in the Treatment of Aortic Aneurysms","has_exemption":false,"start_date":"2012-01-25","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"Baptist Health South Florida","sponsor_slug":"baptist-health-south-florida","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT01893307","publication_url":"https://clinicaltrials.gov/study/NCT01893307","title":"Phase III Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) Versus Intensity-Modulated Photon Therapy (IMRT) for the Treatment of Oropharyngeal Cancer of the Head and Neck","has_exemption":false,"start_date":"2013-08-26","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT01712620","publication_url":"https://clinicaltrials.gov/study/NCT01712620","title":"A Pilot Study of the Effect of Spironolactone Therapy on Exercise Capacity and Endothelial Dysfunction in Pulmonary Arterial Hypertension","has_exemption":false,"start_date":"2014-01-10","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"National Institutes of Health Clinical Center (CC)","sponsor_slug":"national-institutes-of-health-clinical-center-cc","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT02579967","publication_url":"https://clinicaltrials.gov/study/NCT02579967","title":"Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies","has_exemption":false,"start_date":"2015-11-19","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT03767595","publication_url":"https://clinicaltrials.gov/study/NCT03767595","title":"Post Approval Study of the ProACT™ Adjustable Continence Therapy for Men","has_exemption":false,"start_date":"2019-02-19","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"Uromedica","sponsor_slug":"uromedica","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03984643","publication_url":"https://clinicaltrials.gov/study/NCT03984643","title":"Algorithms for Programming DBS Systems for ET","has_exemption":false,"start_date":"2019-10-01","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"University of Minnesota","sponsor_slug":"university-of-minnesota","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04586166","publication_url":"https://clinicaltrials.gov/study/NCT04586166","title":"SASS: Randomized Trial of Single-incision Versus Retropubic Mid-Urethral Sling (Solyx) for Concomitant Management of Stress Urinary Incontinence During Minimally Invasive Sacrocolpopexy","has_exemption":false,"start_date":"2020-12-23","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"Wake Forest University Health Sciences","sponsor_slug":"wake-forest-university-health-sciences","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04124341","publication_url":"https://clinicaltrials.gov/study/NCT04124341","title":"Prefrontal Cortical Stimulation (PCS) for Severe Treatment Resistant Depression","has_exemption":false,"start_date":"2021-09-29","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"University of Minnesota","sponsor_slug":"university-of-minnesota","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05232916","publication_url":"https://clinicaltrials.gov/study/NCT05232916","title":"A Randomized, Multicenter, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects With Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01)","has_exemption":false,"start_date":"2022-12-16","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"Greenwich LifeSciences, Inc.","sponsor_slug":"greenwich-lifesciences-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05478304","publication_url":"https://clinicaltrials.gov/study/NCT05478304","title":"Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial","has_exemption":false,"start_date":"2023-01-25","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"AtriCure, Inc.","sponsor_slug":"atricure-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05900401","publication_url":"https://clinicaltrials.gov/study/NCT05900401","title":"Delayed Tolerance Through Mixed Chimerism","has_exemption":false,"start_date":"2023-10-01","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"Massachusetts General Hospital","sponsor_slug":"massachusetts-general-hospital","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06134232","publication_url":"https://clinicaltrials.gov/study/NCT06134232","title":"An Open -Label, Multicenter Study of Subjects With Metastatic Castrate-Resistant Prostate Cancer Treated With PROVENGE ® and Boosted With A Single Infusion of Sipuleucel-T to Measure Immune Response","has_exemption":false,"start_date":"2023-10-02","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"Dendreon","sponsor_slug":"dendreon","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06428721","publication_url":"https://clinicaltrials.gov/study/NCT06428721","title":"The Preventive Role of Fractionated Laser Resurfacing Against Actinic Neoplasia in an At-Risk Geriatric Population","has_exemption":false,"start_date":"2024-03-20","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"Wright State University","sponsor_slug":"wright-state-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06529809","publication_url":"https://clinicaltrials.gov/study/NCT06529809","title":"Accelerated Brachytherapy Forward Chemo Radiation Therapy (ABC-RT) for Locally-advanced Cervical Cancer","has_exemption":false,"start_date":"2025-02-11","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"Washington University School of Medicine","sponsor_slug":"washington-university-school-of-medicine","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06390956","publication_url":"https://clinicaltrials.gov/study/NCT06390956","title":"A Phase II Study of Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma","has_exemption":false,"start_date":"2025-02-20","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"University of Utah","sponsor_slug":"university-of-utah","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06951217","publication_url":"https://clinicaltrials.gov/study/NCT06951217","title":"A Multinational, Long-Term, Safety and Tolerability, Open-Label Extension Study of Subjects Who Have Participated in Avalyn Pharma Studies of Inhaled Antifibrotic Agents (AP-LTE-008 [SAIL])","has_exemption":false,"start_date":"2025-04-17","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"Avalyn Pharma Inc.","sponsor_slug":"avalyn-pharma-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07114874","publication_url":"https://clinicaltrials.gov/study/NCT07114874","title":"A Global, Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety and Tolerability of NBI-1117568 in Adults With Schizophrenia","has_exemption":false,"start_date":"2025-07-11","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"Neurocrine Biosciences","sponsor_slug":"neurocrine-biosciences","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07070115","publication_url":"https://clinicaltrials.gov/study/NCT07070115","title":"A Prospective Study Evaluating Clinical Hiatal Hernia Outcomes Using OviTex® Reinforced Tissue Matrix","has_exemption":false,"start_date":"2025-07-25","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"Tela Bio Inc","sponsor_slug":"tela-bio-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07276438","publication_url":"https://clinicaltrials.gov/study/NCT07276438","title":"MRI- or CT-Guidance and Online Adaptation With Stereotactic Radiotherapy for Prostate Cancer (MANTICORE)","has_exemption":false,"start_date":"2025-12-01","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"Jonsson Comprehensive Cancer Center","sponsor_slug":"jonsson-comprehensive-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07195591","publication_url":"https://clinicaltrials.gov/study/NCT07195591","title":"Randomized Study of Resection and GammaTile® Followed by Concurrent External Beam Radiation Therapy (EBRT) and Temozolomide (TMZ) and Adjuvant TMZ Versus Standard of Care in Newly Diagnosed Glioblastoma (GBM)","has_exemption":false,"start_date":"2025-12-10","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"GT Medical Technologies, Inc.","sponsor_slug":"gt-medical-technologies-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07444489","publication_url":"https://clinicaltrials.gov/study/NCT07444489","title":"An Open-Label Long-Term Extension Study of Felzartamab in Participants With Antibody-Mediated Rejection or Microvascular Inflammation Previously Enrolled in TRANSCEND or TRANSPIRE","has_exemption":false,"start_date":"2026-04-16","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"Biogen","sponsor_slug":"biogen","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07554521","publication_url":"https://clinicaltrials.gov/study/NCT07554521","title":"An Open-Label, Single-Arm, Phase 2 Study to Evaluate the Efficacy and Safety of Tislelizumab Plus Chemotherapy in a First-Line Setting for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in US Racial and Ethnic Minority Patients","has_exemption":false,"start_date":"2026-04-30","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"BeOne Medicines","sponsor_slug":"beone-medicines","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07667296","publication_url":"https://clinicaltrials.gov/study/NCT07667296","title":"A Multicenter, Randomized, Open-Label Phase 3 Study of APG-157 as Neoadjuvant Therapy or as Induction and Maintenance Therapy in Locally Advanced Head and Neck Squamous Cell Carcinoma","has_exemption":false,"start_date":"2026-07-31","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"Aveta Biomics, Inc.","sponsor_slug":"aveta-biomics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06694454","publication_url":"https://clinicaltrials.gov/study/NCT06694454","title":"Phase I/II Study of Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)","has_exemption":false,"start_date":"2026-10-25","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07775313","publication_url":"https://clinicaltrials.gov/study/NCT07775313","title":"Phase 1/2 Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM","has_exemption":false,"start_date":"2026-10-25","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","sponsor_slug":"national-institute-of-allergy-and-infectious-diseases-niaid","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07513623","publication_url":"https://clinicaltrials.gov/study/NCT07513623","title":"Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II","has_exemption":false,"start_date":"2026-11-01","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"University of California, San Francisco","sponsor_slug":"university-of-california-san-francisco","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07158606","publication_url":"https://clinicaltrials.gov/study/NCT07158606","title":"Understanding Treatment Outcomes and Immunologic Mechanisms in ALtuviiio Immune Tolerance Induction","has_exemption":false,"start_date":"2026-12-01","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"Versiti Blood Health","sponsor_slug":"versiti-blood-health","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07768618","publication_url":"https://clinicaltrials.gov/study/NCT07768618","title":"Electrophysiologic Dynamics of Depression and Antidepressant Response in Epilepsy","has_exemption":false,"start_date":"2026-12-31","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"Emory University","sponsor_slug":"emory-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07862712","publication_url":"https://clinicaltrials.gov/study/NCT07862712","title":"From Hyperarousal to Hyperglycemia: Therapeutic Targeting of Noradrenergic Signaling in PTSD-Related Insulin Resistance","has_exemption":false,"start_date":"2027-03-01","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"VA Office of Research and Development","sponsor_slug":"va-office-of-research-and-development","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07705282","publication_url":"https://clinicaltrials.gov/study/NCT07705282","title":"Standalone Thoracoscopic Left Atrial Appendage Closure Versus Medical Therapy in Atrial Fibrillation","has_exemption":false,"start_date":"2028-01-01","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"Region Skane","sponsor_slug":"region-skane","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07106125","publication_url":"https://clinicaltrials.gov/study/NCT07106125","title":"Trial of Antibiotic Strategies for Kidney Transplant Recipients","has_exemption":false,"start_date":"2028-10-31","completion_date":"2031-12-31","has_results":false,"results_due":false,"sponsor_name":"University of California, San Francisco","sponsor_slug":"university-of-california-san-francisco","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07542756","publication_url":"https://clinicaltrials.gov/study/NCT07542756","title":"Sequential Multiple Assignment Randomized Trial Comparing Commonly Prescribed and Over the Counter Medications for the Treatment of Insomnia in Adults","has_exemption":false,"start_date":"2026-05-01","completion_date":"2032-01-01","has_results":false,"results_due":false,"sponsor_name":"University of Pennsylvania","sponsor_slug":"university-of-pennsylvania","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07565155","publication_url":"https://clinicaltrials.gov/study/NCT07565155","title":"A Phase 2 Trial of Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency","has_exemption":false,"start_date":"2027-01-01","completion_date":"2032-01-01","has_results":false,"results_due":false,"sponsor_name":"University of Miami","sponsor_slug":"university-of-miami","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07689240","publication_url":"https://clinicaltrials.gov/study/NCT07689240","title":"Phase III Study of Adjuvant Pembrolizumab vs Active Surveillance After Nephrectomy in Patients With Non-Clear Cell Renal-Cell Carcinoma","has_exemption":false,"start_date":"2027-02-10","completion_date":"2032-01-01","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06745076","publication_url":"https://clinicaltrials.gov/study/NCT06745076","title":"A Multicenter Study PRECISE-HL: Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation in Advanced Hodgkin Lymphoma","has_exemption":false,"start_date":"2025-03-06","completion_date":"2032-01-03","has_results":false,"results_due":false,"sponsor_name":"University of Washington","sponsor_slug":"university-of-washington","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06780111","publication_url":"https://clinicaltrials.gov/study/NCT06780111","title":"A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06E","has_exemption":false,"start_date":"2025-07-30","completion_date":"2032-01-04","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06971939","publication_url":"https://clinicaltrials.gov/study/NCT06971939","title":"A Phase 4, Multicenter, Open-label Study to Evaluate Long-term Safety and Efficacy of Revakinagene Taroretcel-Lwey (NT-501) Previously Implanted During a Phase 1, Phase 2, or Phase 3 Clinical Study and to Evaluate NT-501 Implanted in Participants Who Underwent the Sham Procedure in a Phase 3 Clinical Study of Macular Telangiectasia Type 2 (MacTel)","has_exemption":false,"start_date":"2025-11-21","completion_date":"2032-01-15","has_results":false,"results_due":false,"sponsor_name":"Neurotech Pharmaceuticals","sponsor_slug":"neurotech-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07022678","publication_url":"https://clinicaltrials.gov/study/NCT07022678","title":"A Randomized Double-Blinded Trial of Xylitol Dental Wipes for the Prophylaxis of Bloodstream Infections From Oral Organisms in Pediatric Patients With Acute Myeloid Leukemia","has_exemption":false,"start_date":"2026-08-14","completion_date":"2032-01-15","has_results":false,"results_due":false,"sponsor_name":"Children's Oncology Group","sponsor_slug":"childrens-oncology-group","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07846020","publication_url":"https://clinicaltrials.gov/study/NCT07846020","title":"Mechanistic Evaluation of Gabapentin and Opioid Polypharmacy","has_exemption":false,"start_date":"2027-01-15","completion_date":"2032-01-15","has_results":false,"results_due":false,"sponsor_name":"University of Maryland, Baltimore","sponsor_slug":"university-of-maryland-baltimore","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07420530","publication_url":"https://clinicaltrials.gov/study/NCT07420530","title":"Respiratory and Real-time Dynamics in Exercise-Induced Paradoxical Vocal Fold Motion","has_exemption":false,"start_date":"2026-08-12","completion_date":"2032-01-20","has_results":false,"results_due":false,"sponsor_name":"Indiana University","sponsor_slug":"indiana-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07218887","publication_url":"https://clinicaltrials.gov/study/NCT07218887","title":"A Phase 1/2, Open-Label, Multicenter, Dose Finding and Dose Expansion Study to Investigate the Safety, Tolerability, and Efficacy of ALXN2350 Gene Therapy in Adult Participants With BAG3 Mutation Associated Dilated Cardiomyopathy","has_exemption":false,"start_date":"2025-10-24","completion_date":"2032-01-27","has_results":false,"results_due":false,"sponsor_name":"Alexion Pharmaceuticals, Inc.","sponsor_slug":"alexion-pharmaceuticals-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05789082","publication_url":"https://clinicaltrials.gov/study/NCT05789082","title":"A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation","has_exemption":false,"start_date":"2023-06-20","completion_date":"2032-01-29","has_results":false,"results_due":false,"sponsor_name":"Hoffmann-La Roche","sponsor_slug":"hoffmann-la-roche","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07621796","publication_url":"https://clinicaltrials.gov/study/NCT07621796","title":"Efficacy and Safety of Tenecteplase Among acutE Ischemic Stroke Patients With Recent Ingestion of Direct Oral Anticoagulant (ESTER-DOAC)","has_exemption":false,"start_date":"2027-01-01","completion_date":"2032-01-30","has_results":false,"results_due":false,"sponsor_name":"Hackensack Meridian Health","sponsor_slug":"hackensack-meridian-health","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06790693","publication_url":"https://clinicaltrials.gov/study/NCT06790693","title":"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer","has_exemption":false,"start_date":"2025-04-09","completion_date":"2032-01-31","has_results":false,"results_due":false,"sponsor_name":"Hoffmann-La Roche","sponsor_slug":"hoffmann-la-roche","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07214688","publication_url":"https://clinicaltrials.gov/study/NCT07214688","title":"A Phase 2 Study of Fludarabine and Intermediate-dose Total Body Irradiation (800 cGy) Followed by Post-transplant Cyclophosphamide in Patients Aged 18-65 Undergoing Allogeneic Stem Cell Transplant for Hematologic Malignancies","has_exemption":false,"start_date":"2026-01-06","completion_date":"2032-01-31","has_results":false,"results_due":false,"sponsor_name":"Hackensack Meridian Health","sponsor_slug":"hackensack-meridian-health","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07303894","publication_url":"https://clinicaltrials.gov/study/NCT07303894","title":"Randomized, Multi-dose, Placebo-controlled Phase 2 Trial of Oral Isoquercetin to Reduce Thrombin Generation in Ovarian Cancer","has_exemption":false,"start_date":"2026-01-22","completion_date":"2032-01-31","has_results":false,"results_due":false,"sponsor_name":"Memorial Sloan Kettering Cancer Center","sponsor_slug":"memorial-sloan-kettering-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07541170","publication_url":"https://clinicaltrials.gov/study/NCT07541170","title":"A Phase III, Randomized, Open-label Study Evaluating the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Patients With Resected Stage II-III KRAS G12C-Positive Non-small Cell Lung Cancer","has_exemption":false,"start_date":"2026-10-06","completion_date":"2032-01-31","has_results":false,"results_due":false,"sponsor_name":"Hoffmann-La Roche","sponsor_slug":"hoffmann-la-roche","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07766421","publication_url":"https://clinicaltrials.gov/study/NCT07766421","title":"An Open-Label, Multicenter, Randomized, Phase 3 Trial of Iopofosine I 131 Versus Rituximab-Cyclophosphamide-Dexamethasone (R-CD) in Waldenstrom Macroglobulinemia Patients Previously Treated With a Bruton Tyrosine Kinase Inhibitor","has_exemption":false,"start_date":"2026-12-31","completion_date":"2032-01-31","has_results":false,"results_due":false,"sponsor_name":"Cellectar Biosciences, Inc.","sponsor_slug":"cellectar-biosciences-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06770582","publication_url":"https://clinicaltrials.gov/study/NCT06770582","title":"Randomized Phase II Trial of Pembrolizumab and Radiation vs. Radiation and Concurrent Chemotherapy for High-Grade T1 Bladder Cancer (PARRC Trial)","has_exemption":false,"start_date":"2025-06-03","completion_date":"2032-02-01","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06686121","publication_url":"https://clinicaltrials.gov/study/NCT06686121","title":"IMProving Mobility After revasCularizaTion in Peripheral Artery Disease: The IMPACT PAD Trial","has_exemption":false,"start_date":"2025-08-04","completion_date":"2032-02-01","has_results":false,"results_due":false,"sponsor_name":"Northwestern University","sponsor_slug":"northwestern-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07774702","publication_url":"https://clinicaltrials.gov/study/NCT07774702","title":"Psilocybin in the Treatment of Methamphetamine Use Disorder","has_exemption":false,"start_date":"2027-02-01","completion_date":"2032-02-01","has_results":false,"results_due":false,"sponsor_name":"Peter Hendricks","sponsor_slug":"peter-hendricks","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06788912","publication_url":"https://clinicaltrials.gov/study/NCT06788912","title":"KEYMAKER-U01 Substudy 01E: A Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With or Without Chemotherapy in Combination With Pembrolizumab in Treatment of Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)","has_exemption":false,"start_date":"2025-03-20","completion_date":"2032-02-06","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04165070","publication_url":"https://clinicaltrials.gov/study/NCT04165070","title":"KEYMAKER-U01 Substudy 01A: A Phase 1/2, Umbrella Study With Rolling Arms of Investigational Agents With Pembrolizumab With or Without Chemotherapy in Treatment-Naive Participants With Stage IV Non-small Cell Lung Cancer (NSCLC)","has_exemption":false,"start_date":"2019-12-19","completion_date":"2032-02-13","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05533697","publication_url":"https://clinicaltrials.gov/study/NCT05533697","title":"Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors","has_exemption":false,"start_date":"2022-09-01","completion_date":"2032-02-18","has_results":false,"results_due":false,"sponsor_name":"ModernaTX, Inc.","sponsor_slug":"modernatx-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06057402","publication_url":"https://clinicaltrials.gov/study/NCT06057402","title":"ELRANATAMAB POST TRIAL ACCESS: AN OPEN-LABEL, SINGLE-ARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER-SPONSORED ELRANATAMAB CLINICAL STUDIES","has_exemption":false,"start_date":"2023-10-03","completion_date":"2032-02-22","has_results":false,"results_due":false,"sponsor_name":"Pfizer","sponsor_slug":"pfizer","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06807281","publication_url":"https://clinicaltrials.gov/study/NCT06807281","title":"A Phase 3, Multicenter, Long-Term, Open Label Study Evaluating the Safety and Efficacy of Abrocitinib, With or Without Topical Medications Administered to Pediatric Participants Aged 2 Years and Older With Moderate-to-Severe Atopic Dermatitis","has_exemption":false,"start_date":"2025-12-02","completion_date":"2032-02-22","has_results":false,"results_due":false,"sponsor_name":"Pfizer","sponsor_slug":"pfizer","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07195695","publication_url":"https://clinicaltrials.gov/study/NCT07195695","title":"Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared With Standard of Care in Patients With Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations","has_exemption":false,"start_date":"2026-01-16","completion_date":"2032-02-26","has_results":false,"results_due":false,"sponsor_name":"Boehringer Ingelheim","sponsor_slug":"boehringer-ingelheim","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07227402","publication_url":"https://clinicaltrials.gov/study/NCT07227402","title":"A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)","has_exemption":false,"start_date":"2025-11-26","completion_date":"2032-02-27","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04774718","publication_url":"https://clinicaltrials.gov/study/NCT04774718","title":"A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available","has_exemption":false,"start_date":"2021-09-14","completion_date":"2032-02-28","has_results":false,"results_due":false,"sponsor_name":"Hoffmann-La Roche","sponsor_slug":"hoffmann-la-roche","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06692712","publication_url":"https://clinicaltrials.gov/study/NCT06692712","title":"Intrathecal Administration of MELPIDA (AAV9/AP4M1) For Hereditary Spastic Paraplegia Type 50 (SPG50): A Phase 3, Open-Label Trial With Matched Prospective Concurrent Control Arm","has_exemption":false,"start_date":"2026-04-01","completion_date":"2032-02-28","has_results":false,"results_due":false,"sponsor_name":"Elpida Therapeutics SPC","sponsor_slug":"elpida-therapeutics-spc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05143840","publication_url":"https://clinicaltrials.gov/study/NCT05143840","title":"Asciminib as Initial Therapy With Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia Who do Not Achieve Optimal Response or a Deep Molecular Remission (ALERT CML)","has_exemption":false,"start_date":"2022-04-22","completion_date":"2032-02-29","has_results":false,"results_due":false,"sponsor_name":"University of Alabama at Birmingham","sponsor_slug":"university-of-alabama-at-birmingham","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06073821","publication_url":"https://clinicaltrials.gov/study/NCT06073821","title":"A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia","has_exemption":false,"start_date":"2023-11-11","completion_date":"2032-02-29","has_results":false,"results_due":false,"sponsor_name":"BeOne Medicines","sponsor_slug":"beone-medicines","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06544798","publication_url":"https://clinicaltrials.gov/study/NCT06544798","title":"Long-term Follow-up of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia","has_exemption":false,"start_date":"2024-08-02","completion_date":"2032-02-29","has_results":false,"results_due":false,"sponsor_name":"MeiraGTx, LLC","sponsor_slug":"meiragtx-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06788522","publication_url":"https://clinicaltrials.gov/study/NCT06788522","title":"The Effects of Orexin Antagonism on Fear Extinction in PTSD","has_exemption":false,"start_date":"2026-06-01","completion_date":"2032-03-01","has_results":false,"results_due":false,"sponsor_name":"VA Office of Research and Development","sponsor_slug":"va-office-of-research-and-development","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06780098","publication_url":"https://clinicaltrials.gov/study/NCT06780098","title":"KEYMAKER-U01 Substudy 01I: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC)","has_exemption":false,"start_date":"2025-05-28","completion_date":"2032-03-02","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06731907","publication_url":"https://clinicaltrials.gov/study/NCT06731907","title":"KEYMAKER-U01 Substudy 01G: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents in Combination With Pembrolizumab With or Without Platinum-based Chemotherapy in Treatment-Naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC)","has_exemption":false,"start_date":"2025-03-30","completion_date":"2032-03-12","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06780085","publication_url":"https://clinicaltrials.gov/study/NCT06780085","title":"KEYMAKER-U01 Substudy 01H: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC)","has_exemption":false,"start_date":"2025-05-13","completion_date":"2032-03-12","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07768358","publication_url":"https://clinicaltrials.gov/study/NCT07768358","title":"TUCATINIB CONTINUATION PROTOCOL: AN OPEN-LABEL STUDY FOR PARTICIPANTS FROM TUCATINIB CLINICAL STUDIES","has_exemption":false,"start_date":"2026-11-06","completion_date":"2032-03-13","has_results":false,"results_due":false,"sponsor_name":"Pfizer","sponsor_slug":"pfizer","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06991556","publication_url":"https://clinicaltrials.gov/study/NCT06991556","title":"A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)","has_exemption":false,"start_date":"2025-07-07","completion_date":"2032-03-15","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07776691","publication_url":"https://clinicaltrials.gov/study/NCT07776691","title":"A Phase 3, Randomized, Open-label Study of Raludotatug Deruxtecan (MK-5909, R-DXd) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly-Diagnosed Advanced Non-HRD-Positive Ovarian Cancer Following First-line Platinum-based Chemotherapy (ENGOT-ov102/MITO/GOG-3141/ REJOICE-Ovarian 04)","has_exemption":false,"start_date":"2026-09-18","completion_date":"2032-03-19","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06351592","publication_url":"https://clinicaltrials.gov/study/NCT06351592","title":"First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ALN-SOD in Participants With Amyotrophic Lateral Sclerosis and SOD1 Mutations","has_exemption":false,"start_date":"2024-08-28","completion_date":"2032-03-21","has_results":false,"results_due":false,"sponsor_name":"Regeneron Pharmaceuticals","sponsor_slug":"regeneron-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07022483","publication_url":"https://clinicaltrials.gov/study/NCT07022483","title":"A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy With or Without Radiotherapy as Adjuvant Treatment for HER2-Expressing (IHC 3+/2+) Endometrial Cancer (DESTINY-Endometrial02/ GOG-3122/ ENGOT-en30/GINECO)","has_exemption":false,"start_date":"2025-09-30","completion_date":"2032-03-23","has_results":false,"results_due":false,"sponsor_name":"Daiichi Sankyo","sponsor_slug":"daiichi-sankyo","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05682378","publication_url":"https://clinicaltrials.gov/study/NCT05682378","title":"An Open-label, Single Arm, Multicenter Extension Study to Evaluate Long-term Safety and Tolerability of Inclisiran in Participants With Heterozygous or Homozygous Familial Hypercholesterolemia Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20 or ORION-19 Studies (VICTORION-PEDS-OLE)","has_exemption":false,"start_date":"2023-02-10","completion_date":"2032-03-25","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03959085","publication_url":"https://clinicaltrials.gov/study/NCT03959085","title":"A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy","has_exemption":false,"start_date":"2019-10-31","completion_date":"2032-03-31","has_results":false,"results_due":false,"sponsor_name":"Children's Oncology Group","sponsor_slug":"childrens-oncology-group","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05064540","publication_url":"https://clinicaltrials.gov/study/NCT05064540","title":"JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization","has_exemption":false,"start_date":"2021-09-20","completion_date":"2032-03-31","has_results":false,"results_due":false,"sponsor_name":"Endologix","sponsor_slug":"endologix","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06337318","publication_url":"https://clinicaltrials.gov/study/NCT06337318","title":"Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma","has_exemption":false,"start_date":"2024-10-23","completion_date":"2032-03-31","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07110246","publication_url":"https://clinicaltrials.gov/study/NCT07110246","title":"A Phase 2 De-escalation Study of Dabrafenib and Trametinib for Patients With BRAF V600 Mutant Low-Grade Gliomas","has_exemption":false,"start_date":"2025-11-07","completion_date":"2032-03-31","has_results":false,"results_due":false,"sponsor_name":"University of California, San Francisco","sponsor_slug":"university-of-california-san-francisco","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07294677","publication_url":"https://clinicaltrials.gov/study/NCT07294677","title":"CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL","has_exemption":false,"start_date":"2026-03-17","completion_date":"2032-03-31","has_results":false,"results_due":false,"sponsor_name":"University of Chicago","sponsor_slug":"university-of-chicago","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07772492","publication_url":"https://clinicaltrials.gov/study/NCT07772492","title":"A Phase 3 Randomized, Placebo-controlled, Double-blind Study to Evaluate Efficacy and Safety of Upadacitinib in Pediatric Subjects With Severe Alopecia Areata","has_exemption":false,"start_date":"2026-08-24","completion_date":"2032-03-31","has_results":false,"results_due":false,"sponsor_name":"AbbVie","sponsor_slug":"abbvie","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07682129","publication_url":"https://clinicaltrials.gov/study/NCT07682129","title":"A Phase 2, Open-Label Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)","has_exemption":false,"start_date":"2026-08-31","completion_date":"2032-03-31","has_results":false,"results_due":false,"sponsor_name":"Entrada Therapeutics, Inc.","sponsor_slug":"entrada-therapeutics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07723651","publication_url":"https://clinicaltrials.gov/study/NCT07723651","title":"Integration of FTT-PET and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)","has_exemption":false,"start_date":"2026-09-01","completion_date":"2032-03-31","has_results":false,"results_due":false,"sponsor_name":"Washington University School of Medicine","sponsor_slug":"washington-university-school-of-medicine","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07645300","publication_url":"https://clinicaltrials.gov/study/NCT07645300","title":"LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD (LODESTAR) Trial","has_exemption":false,"start_date":"2026-10-01","completion_date":"2032-03-31","has_results":false,"results_due":false,"sponsor_name":"VA Office of Research and Development","sponsor_slug":"va-office-of-research-and-development","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07840521","publication_url":"https://clinicaltrials.gov/study/NCT07840521","title":"Investigating Near-Threshold Perception During Ultrasonic Deep Brain Stimulation","has_exemption":false,"start_date":"2026-11-30","completion_date":"2032-03-31","has_results":false,"results_due":false,"sponsor_name":"University of Michigan","sponsor_slug":"university-of-michigan","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06649747","publication_url":"https://clinicaltrials.gov/study/NCT06649747","title":"A Double-blind, Placebo-controlled, Multi-center Phase II Study of the Safety, Tolerability, Efficacy and Pharmacokinetics of Oral AFA-281 in Patients With Painful Lumbosacral Radiculopathy","has_exemption":false,"start_date":"2027-04-01","completion_date":"2032-03-31","has_results":false,"results_due":false,"sponsor_name":"Afasci Inc","sponsor_slug":"afasci-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07572747","publication_url":"https://clinicaltrials.gov/study/NCT07572747","title":"Aspirin Versus Clopidogrel for Secondary Prevention of Atherosclerotic Cardiovascular Events in Patients With Chronic Coronary Syndrome in the Arabian Gulf Countries: A Randomized, Open-label, Multi-Center Trial by the Gulf Trialists' Collaboration","has_exemption":false,"start_date":"2027-04-01","completion_date":"2032-04-01","has_results":false,"results_due":false,"sponsor_name":"Khalid F Alhabib","sponsor_slug":"khalid-f-alhabib","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07209111","publication_url":"https://clinicaltrials.gov/study/NCT07209111","title":"A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination With Cetuximab, in Participants With KRAS G12C-Mutant, Advanced Solid Tumors (KANDLELIT-014)","has_exemption":false,"start_date":"2025-12-04","completion_date":"2032-04-09","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07819838","publication_url":"https://clinicaltrials.gov/study/NCT07819838","title":"A Phase 1/2 Study of Daraxonrasib (RMC-6236) in Patients With Relapsed or Refractory RAS-Driven Tumors","has_exemption":false,"start_date":"2027-04-09","completion_date":"2032-04-09","has_results":false,"results_due":false,"sponsor_name":"Children's Oncology Group","sponsor_slug":"childrens-oncology-group","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05714085","publication_url":"https://clinicaltrials.gov/study/NCT05714085","title":"A Phase 2/3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Systemic Left Ventricular Systolic Dysfunction (VALOR)","has_exemption":false,"start_date":"2023-05-31","completion_date":"2032-04-15","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06422806","publication_url":"https://clinicaltrials.gov/study/NCT06422806","title":"A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Dedifferentiated Liposarcoma (DDLPS), Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas","has_exemption":false,"start_date":"2024-09-11","completion_date":"2032-04-18","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06666322","publication_url":"https://clinicaltrials.gov/study/NCT06666322","title":"Platform Trial For Cryptococcal Meningitis","has_exemption":false,"start_date":"2025-05-28","completion_date":"2032-04-21","has_results":false,"results_due":false,"sponsor_name":"David Boulware","sponsor_slug":"david-boulware","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06229210","publication_url":"https://clinicaltrials.gov/study/NCT06229210","title":"An Open-label, Multicenter Trial to Assess the Safety and Tolerability of Lumateperone in the Treatment of Pediatric Patients With Schizophrenia, Bipolar Disorder, or Autism Spectrum Disorder","has_exemption":false,"start_date":"2024-01-25","completion_date":"2032-04-28","has_results":false,"results_due":false,"sponsor_name":"Intra-Cellular Therapies, Inc.","sponsor_slug":"intra-cellular-therapies-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07612254","publication_url":"https://clinicaltrials.gov/study/NCT07612254","title":"REPEAT: RE-irradiation With a Partial brEast, Accelerated Technique: A Single-Center, Multi-site, Prospective, Phase I/II Clinical Trial","has_exemption":false,"start_date":"2026-06-03","completion_date":"2032-04-28","has_results":false,"results_due":false,"sponsor_name":"Dartmouth-Hitchcock Medical Center","sponsor_slug":"dartmouth-hitchcock-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04114136","publication_url":"https://clinicaltrials.gov/study/NCT04114136","title":"A Phase II Clinical Trial of Anti-PD-1 mAb Therapy Alone or With Metabolic Modulators to Reverse Tumor Hypoxia and Immune Dysfunction in Solid Tumor Malignancies","has_exemption":false,"start_date":"2020-09-14","completion_date":"2032-04-30","has_results":false,"results_due":false,"sponsor_name":"Dan Zandberg","sponsor_slug":"dan-zandberg","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04093349","publication_url":"https://clinicaltrials.gov/study/NCT04093349","title":"Phase 1/2, Dose-escalation Study to Evaluate the Safety, Tolerability and Efficacy of a Single Intravenous Infusion of SPK-3006 in Adults With Late-onset Pompe Disease","has_exemption":false,"start_date":"2020-10-01","completion_date":"2032-04-30","has_results":false,"results_due":false,"sponsor_name":"Spark Therapeutics, Inc.","sponsor_slug":"spark-therapeutics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05031897","publication_url":"https://clinicaltrials.gov/study/NCT05031897","title":"A 2 Step Approach to Haploidentical Transplant Using Radiation-Based Reduced Intensity Conditioning","has_exemption":false,"start_date":"2021-10-25","completion_date":"2032-04-30","has_results":false,"results_due":false,"sponsor_name":"Thomas Jefferson University","sponsor_slug":"thomas-jefferson-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05707949","publication_url":"https://clinicaltrials.gov/study/NCT05707949","title":"A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Atogepant in Pediatric Subjects 6 to 17 Years of Age With Migraine","has_exemption":false,"start_date":"2023-06-05","completion_date":"2032-04-30","has_results":false,"results_due":false,"sponsor_name":"AbbVie","sponsor_slug":"abbvie","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05833763","publication_url":"https://clinicaltrials.gov/study/NCT05833763","title":"An Open-label, Single-arm, Phase 2 Trial of GlOfitamab anD pIrtobrutinib (LOXo-305) in Patients With Mantle Cell Lymphoma and Prior Exposure to a BTK Inhibitor","has_exemption":false,"start_date":"2023-10-12","completion_date":"2032-04-30","has_results":false,"results_due":false,"sponsor_name":"Australasian Leukaemia and Lymphoma Group","sponsor_slug":"australasian-leukaemia-and-lymphoma-group","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07226206","publication_url":"https://clinicaltrials.gov/study/NCT07226206","title":"A Phase 2b, Single-Arm, Open-Label, Multicenter Study of the Safety of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A","has_exemption":false,"start_date":"2026-09-08","completion_date":"2032-04-30","has_results":false,"results_due":false,"sponsor_name":"Hoffmann-La Roche","sponsor_slug":"hoffmann-la-roche","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07797283","publication_url":"https://clinicaltrials.gov/study/NCT07797283","title":"A Phase 3, Double-Blind, Randomized, Controlled Study of INCB123667 in Combination With Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Participants With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Overexpressing Cyclin E1 (MAESTRA 3)","has_exemption":false,"start_date":"2026-12-01","completion_date":"2032-05-01","has_results":false,"results_due":false,"sponsor_name":"Incyte Corporation","sponsor_slug":"incyte-corporation","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05352919","publication_url":"https://clinicaltrials.gov/study/NCT05352919","title":"A Multicenter, Randomized, Dose-Blind, Phase 3 Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus","has_exemption":false,"start_date":"2022-06-10","completion_date":"2032-05-03","has_results":false,"results_due":false,"sponsor_name":"Biogen","sponsor_slug":"biogen","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07448610","publication_url":"https://clinicaltrials.gov/study/NCT07448610","title":"Onasemnogene Abeparvovec: ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM)","has_exemption":false,"start_date":"2026-08-27","completion_date":"2032-05-03","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07214532","publication_url":"https://clinicaltrials.gov/study/NCT07214532","title":"SIgnatera-Guided Initiation of Adjuvant CDK4/6 Inhibitor in Intermediate Risk HR+ HER2- Breast Cancer","has_exemption":false,"start_date":"2026-05-08","completion_date":"2032-05-15","has_results":false,"results_due":false,"sponsor_name":"Natera, Inc.","sponsor_slug":"natera-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06140524","publication_url":"https://clinicaltrials.gov/study/NCT06140524","title":"Phase 2 Dose-Ranging and Interception Study of Linvoseltamab in Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma","has_exemption":false,"start_date":"2024-09-16","completion_date":"2032-05-18","has_results":false,"results_due":false,"sponsor_name":"Regeneron Pharmaceuticals","sponsor_slug":"regeneron-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06952504","publication_url":"https://clinicaltrials.gov/study/NCT06952504","title":"A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29)","has_exemption":false,"start_date":"2025-05-22","completion_date":"2032-05-24","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04130997","publication_url":"https://clinicaltrials.gov/study/NCT04130997","title":"An Open Label Extension Study of Ublituximab in Subjects With Relapsing Multiple Sclerosis","has_exemption":false,"start_date":"2019-11-18","completion_date":"2032-05-31","has_results":false,"results_due":false,"sponsor_name":"TG Therapeutics, Inc.","sponsor_slug":"tg-therapeutics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05630053","publication_url":"https://clinicaltrials.gov/study/NCT05630053","title":"Randomized Controlled Trial to Compare Persona OsseoTi Keel Cementless TKA vs Persona Keel Cemented TKA","has_exemption":false,"start_date":"2023-07-25","completion_date":"2032-05-31","has_results":false,"results_due":false,"sponsor_name":"Zimmer Biomet","sponsor_slug":"zimmer-biomet","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05794321","publication_url":"https://clinicaltrials.gov/study/NCT05794321","title":"Investigating the Use of Intravenous Tranexamic Acid in Gender Affirming Mastectomy","has_exemption":false,"start_date":"2023-09-28","completion_date":"2032-05-31","has_results":false,"results_due":false,"sponsor_name":"University of California, San Francisco","sponsor_slug":"university-of-california-san-francisco","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06058377","publication_url":"https://clinicaltrials.gov/study/NCT06058377","title":"Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for Adults With MammaPrint High 2 Risk (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer","has_exemption":false,"start_date":"2023-11-27","completion_date":"2032-05-31","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06374459","publication_url":"https://clinicaltrials.gov/study/NCT06374459","title":"A Phase Ib/II Trial of Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis","has_exemption":false,"start_date":"2025-01-30","completion_date":"2032-05-31","has_results":false,"results_due":false,"sponsor_name":"Washington University School of Medicine","sponsor_slug":"washington-university-school-of-medicine","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06773910","publication_url":"https://clinicaltrials.gov/study/NCT06773910","title":"An Open-label, Randomized Study of BMS-986489 (Atigotatug + Nivolumab Fixed-dose Combination) vs Durvalumab as Consolidation Therapy Following Chemoradiotherapy in Limited-stage Small-cell Lung Cancer (TIGOS-LS)","has_exemption":false,"start_date":"2025-03-11","completion_date":"2032-05-31","has_results":false,"results_due":false,"sponsor_name":"SCRI Development Innovations, LLC","sponsor_slug":"scri-development-innovations-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07005154","publication_url":"https://clinicaltrials.gov/study/NCT07005154","title":"A Phase 2, Open-label, Multi-cohort Study to Assess the Efficacy and Safety of ASP5541 in Participants With Advanced Prostate Cancer","has_exemption":false,"start_date":"2025-08-19","completion_date":"2032-05-31","has_results":false,"results_due":false,"sponsor_name":"Astellas Pharma Global Development, Inc.","sponsor_slug":"astellas-pharma-global-development-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07659678","publication_url":"https://clinicaltrials.gov/study/NCT07659678","title":"CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma","has_exemption":false,"start_date":"2026-10-31","completion_date":"2032-05-31","has_results":false,"results_due":false,"sponsor_name":"Washington University School of Medicine","sponsor_slug":"washington-university-school-of-medicine","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07649603","publication_url":"https://clinicaltrials.gov/study/NCT07649603","title":"Prophylactic Pulmonary Vein Isolation During Atrial Flutter Ablation: The PREVENT-AF Study II","has_exemption":false,"start_date":"2027-06-30","completion_date":"2032-05-31","has_results":false,"results_due":false,"sponsor_name":"University of Rochester","sponsor_slug":"university-of-rochester","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07729046","publication_url":"https://clinicaltrials.gov/study/NCT07729046","title":"Neu Direction: A Single Center Phase II Randomized Clinical Trial to Assess the Efficacy of Adding HER Inhibition to Standard of Care in Patients With Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer","has_exemption":false,"start_date":"2027-07-31","completion_date":"2032-05-31","has_results":false,"results_due":false,"sponsor_name":"University of California, San Diego","sponsor_slug":"university-of-california-san-diego","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05947851","publication_url":"https://clinicaltrials.gov/study/NCT05947851","title":"A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)","has_exemption":false,"start_date":"2023-08-08","completion_date":"2032-06-01","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07816250","publication_url":"https://clinicaltrials.gov/study/NCT07816250","title":"A Phase 2b Randomized, Open-Label Active Controlled Study Evaluating the Safety and Efficacy of 2-drug Injectable Regimens of VH4011499 Plus Cabotegravir in Treatment Naïve Viremic Adult Participants With HIV-1 (CINERGY)","has_exemption":false,"start_date":"2026-10-19","completion_date":"2032-06-10","has_results":false,"results_due":false,"sponsor_name":"ViiV Healthcare","sponsor_slug":"viiv-healthcare","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07717450","publication_url":"https://clinicaltrials.gov/study/NCT07717450","title":"TAILORswitch (PADA-2): Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.","has_exemption":false,"start_date":"2026-09-25","completion_date":"2032-06-25","has_results":false,"results_due":false,"sponsor_name":"UNICANCER","sponsor_slug":"unicancer","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07722611","publication_url":"https://clinicaltrials.gov/study/NCT07722611","title":"A Phase 2/3, Randomized, Open-label, Active-comparator-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543) Versus Best Available Therapy in Participants With Polycythemia Vera Who Have an Inadequate Response to or Are Intolerant to Hydroxyurea","has_exemption":false,"start_date":"2026-10-21","completion_date":"2032-06-25","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04430218","publication_url":"https://clinicaltrials.gov/study/NCT04430218","title":"Peripheral Interfaces in Amputees for Sensorimotor Integration","has_exemption":false,"start_date":"2020-08-18","completion_date":"2032-06-30","has_results":false,"results_due":false,"sponsor_name":"VA Office of Research and Development","sponsor_slug":"va-office-of-research-and-development","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05468359","publication_url":"https://clinicaltrials.gov/study/NCT05468359","title":"ANGIO-A: Safety and Tolerability of Oral Cyclophosphamide and Sorafenib With Intravenous Bevacizumab With the Addition of Atezolizumab in Pediatric Solid Tumor Patients","has_exemption":false,"start_date":"2022-11-07","completion_date":"2032-06-30","has_results":false,"results_due":false,"sponsor_name":"St. Jude Children's Research Hospital","sponsor_slug":"st-jude-childrens-research-hospital","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05425615","publication_url":"https://clinicaltrials.gov/study/NCT05425615","title":"Probing Language Processes Using Transcranial Magnetic Stimulation","has_exemption":false,"start_date":"2024-06-05","completion_date":"2032-06-30","has_results":false,"results_due":false,"sponsor_name":"Medical College of Wisconsin","sponsor_slug":"medical-college-of-wisconsin","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06494501","publication_url":"https://clinicaltrials.gov/study/NCT06494501","title":"The Prevent Coronary Artery Disease Trial","has_exemption":false,"start_date":"2024-09-12","completion_date":"2032-06-30","has_results":false,"results_due":false,"sponsor_name":"Icahn School of Medicine at Mount Sinai","sponsor_slug":"icahn-school-of-medicine-at-mount-sinai","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06483100","publication_url":"https://clinicaltrials.gov/study/NCT06483100","title":"Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance","has_exemption":false,"start_date":"2024-12-20","completion_date":"2032-06-30","has_results":false,"results_due":false,"sponsor_name":"Washington University School of Medicine","sponsor_slug":"washington-university-school-of-medicine","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06940739","publication_url":"https://clinicaltrials.gov/study/NCT06940739","title":"A Phase 1/2, Open-label Study of a Modified Interleukin-2 Fusion Protein (IOV-3001) in Participants With Previously Treated, Unresectable or Metastatic Melanoma Who Will Receive Lifileucel","has_exemption":false,"start_date":"2025-03-11","completion_date":"2032-06-30","has_results":false,"results_due":false,"sponsor_name":"Iovance Biotherapeutics, Inc.","sponsor_slug":"iovance-biotherapeutics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06445114","publication_url":"https://clinicaltrials.gov/study/NCT06445114","title":"ULTRA-HPV Using Circulating Tumor DNA to Risk Adapt Post-operative Therapy for HPV Associated Oropharyngeal Cancer","has_exemption":false,"start_date":"2025-05-12","completion_date":"2032-06-30","has_results":false,"results_due":false,"sponsor_name":"Zachary Zumsteg","sponsor_slug":"zachary-zumsteg","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07721025","publication_url":"https://clinicaltrials.gov/study/NCT07721025","title":"A Phase 2, Multicenter, Open-label, Randomized, Controlled Study of LX2006 Gene Therapy in Participants With Friedreich Ataxia Cardiomyopathy (SUNRISE-FA 2)","has_exemption":false,"start_date":"2026-06-25","completion_date":"2032-06-30","has_results":false,"results_due":false,"sponsor_name":"Lexeo Therapeutics","sponsor_slug":"lexeo-therapeutics","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07581002","publication_url":"https://clinicaltrials.gov/study/NCT07581002","title":"A Randomized Phase 2/3 Study Evaluating the Safety and Efficacy of Pivekimab Sunirine (PVEK) in Combination With Venetoclax and Azacitidine in Adult Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible to Receive Intensive Chemotherapy","has_exemption":false,"start_date":"2026-06-30","completion_date":"2032-06-30","has_results":false,"results_due":false,"sponsor_name":"AbbVie","sponsor_slug":"abbvie","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07624227","publication_url":"https://clinicaltrials.gov/study/NCT07624227","title":"The Impact of Cobenfy Maintenance on Cocaine's Effects","has_exemption":false,"start_date":"2026-08-01","completion_date":"2032-06-30","has_results":false,"results_due":false,"sponsor_name":"Joshua A. Lile, Ph.D.","sponsor_slug":"joshua-a-lile-phd","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07541079","publication_url":"https://clinicaltrials.gov/study/NCT07541079","title":"A Phase IIIb, Single-Arm, Open-Label Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes (PRO) of Giredestrant in Patients With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy","has_exemption":false,"start_date":"2026-08-25","completion_date":"2032-06-30","has_results":false,"results_due":false,"sponsor_name":"Genentech, Inc.","sponsor_slug":"genentech-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06122974","publication_url":"https://clinicaltrials.gov/study/NCT06122974","title":"A RanDomized Controlled Trial of the Drug Eluting TEmporary Spur StEnt System vs PERcutaneous Balloon Angioplasty for the TReatment of CriTical Limb Ischemia","has_exemption":false,"start_date":"2026-08-31","completion_date":"2032-06-30","has_results":false,"results_due":false,"sponsor_name":"ReFlow Medical, Inc.","sponsor_slug":"reflow-medical-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06900998","publication_url":"https://clinicaltrials.gov/study/NCT06900998","title":"A Pilot Study on the Effects of Nimodipine on Alcohol Drinking Among Adults Who Are Heavy Alcohol Drinkers","has_exemption":false,"start_date":"2026-09-01","completion_date":"2032-06-30","has_results":false,"results_due":false,"sponsor_name":"Yale University","sponsor_slug":"yale-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07681869","publication_url":"https://clinicaltrials.gov/study/NCT07681869","title":"A Randomized Controlled Study on the Effects of Nimodipine on Alcohol Drinking Among Adults Who Are Heavy Alcohol Drinkers","has_exemption":false,"start_date":"2026-09-01","completion_date":"2032-06-30","has_results":false,"results_due":false,"sponsor_name":"Yale University","sponsor_slug":"yale-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07675954","publication_url":"https://clinicaltrials.gov/study/NCT07675954","title":"A Phase 3, Open-Label, Randomised Controlled Trial to Evaluate a 6-Month \"MDR-END Plus\" Regimen (Bedaquiline, Delamanid, Delpazolid, Levofloxacin and Pyrazinamide) Versus the South African Standard of Care Treatment for Rifampicin-Resistant Tuberculosis","has_exemption":false,"start_date":"2026-10-01","completion_date":"2032-06-30","has_results":false,"results_due":false,"sponsor_name":"Seoul National University Hospital","sponsor_slug":"seoul-national-university-hospital","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07389278","publication_url":"https://clinicaltrials.gov/study/NCT07389278","title":"A Phase 1/2 Study of Pegylated Arginine Deiminase (ADI-PEG 20) Plus Radiotherapy (RT) and Temozolomide (TMZ) in Children, Adolescents, and Young Adults With Newly Diagnosed High-grade Glioma (HGG)","has_exemption":false,"start_date":"2027-06-01","completion_date":"2032-06-30","has_results":false,"results_due":false,"sponsor_name":"Sabine Mueller, MD, PhD","sponsor_slug":"sabine-mueller-md-phd","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07179003","publication_url":"https://clinicaltrials.gov/study/NCT07179003","title":"A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses","has_exemption":false,"start_date":"2027-07-31","completion_date":"2032-06-30","has_results":false,"results_due":false,"sponsor_name":"University of Rochester","sponsor_slug":"university-of-rochester","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07817186","publication_url":"https://clinicaltrials.gov/study/NCT07817186","title":"Clinical Trial of a MEK Inhibitor for RASopathy-Associated Severe Infantile Hypertrophic Cardiomyopathy: Baby MERIT","has_exemption":false,"start_date":"2027-08-01","completion_date":"2032-06-30","has_results":false,"results_due":false,"sponsor_name":"Carelon Research","sponsor_slug":"carelon-research","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04175431","publication_url":"https://clinicaltrials.gov/study/NCT04175431","title":"Prostate Specific Membrane Antigen (PSMA) or Fluciclovine (FACBC) PET/CT Site-Directed Therapy of OLigometASTatic Prostate Cancer (P-Flu-BLAST-PC): A Multicenter Study","has_exemption":false,"start_date":"2020-09-30","completion_date":"2032-07-01","has_results":false,"results_due":false,"sponsor_name":"University of Washington","sponsor_slug":"university-of-washington","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06087263","publication_url":"https://clinicaltrials.gov/study/NCT06087263","title":"Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.","has_exemption":false,"start_date":"2024-06-18","completion_date":"2032-07-01","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05814432","publication_url":"https://clinicaltrials.gov/study/NCT05814432","title":"Efficacy and Safety of High-dose Liposomal Amphotericin B (10 mg/kg) for Disseminated Histoplasmosis in AIDS: a Randomized Phase III Trial (INDUCTION Trial)","has_exemption":false,"start_date":"2025-01-16","completion_date":"2032-07-01","has_results":false,"results_due":false,"sponsor_name":"Federal University of Health Science of Porto Alegre","sponsor_slug":"federal-university-of-health-science-of-porto-alegre","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07026942","publication_url":"https://clinicaltrials.gov/study/NCT07026942","title":"A Phase I/II Clinical Trial Evaluating the Safety and Efficacy of Universal Donor CD33 CAR Natural Killer Cells for Treatment of Relapsed/Refractory Acute Myeloid Leukemia","has_exemption":false,"start_date":"2026-04-01","completion_date":"2032-07-01","has_results":false,"results_due":false,"sponsor_name":"Nationwide Children's Hospital","sponsor_slug":"nationwide-childrens-hospital","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07798271","publication_url":"https://clinicaltrials.gov/study/NCT07798271","title":"Optimizing Adaptive Deep Brain Stimulation for Parkinson's Disease","has_exemption":false,"start_date":"2026-05-08","completion_date":"2032-07-01","has_results":false,"results_due":false,"sponsor_name":"University of California, Davis","sponsor_slug":"university-of-california-davis","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06991738","publication_url":"https://clinicaltrials.gov/study/NCT06991738","title":"Phase 1/2, Open-Label Study of the Safety, Dosimetry and Efficacy of a 3-Dose Regimen of Escalating Doses of 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer","has_exemption":false,"start_date":"2026-10-25","completion_date":"2032-07-01","has_results":false,"results_due":false,"sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","sponsor_slug":"national-institute-of-diabetes-and-digestive-and-kidney-diseases-niddk","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07856719","publication_url":"https://clinicaltrials.gov/study/NCT07856719","title":"COINCIDE-RT: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Single-Center Trial Of Low-Dose Colchicine For The Prevention Of Radiation-Induced Carotid Artery Disease In Survivors Of Head And Neck Cancer (Colchicine For Inflammatory Carotid Injury And Disease Evolution After Radiotherapy [COINCIDE-RT])","has_exemption":false,"start_date":"2027-03-01","completion_date":"2032-07-01","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05076175","publication_url":"https://clinicaltrials.gov/study/NCT05076175","title":"A Phase 2/3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis With an Inadequate Response to Conventional Therapy","has_exemption":false,"start_date":"2022-05-30","completion_date":"2032-07-12","has_results":false,"results_due":false,"sponsor_name":"Bristol-Myers Squibb","sponsor_slug":"bristol-myers-squibb","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07213830","publication_url":"https://clinicaltrials.gov/study/NCT07213830","title":"An Open-label, Phase I/II First in Human, Dose Escalation, Optimisation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Participants With Locally Advanced or Metastatic Solid Tumours Who Have Progressed on or After Immune Checkpoint Inhibitor Therapies","has_exemption":false,"start_date":"2026-02-06","completion_date":"2032-07-14","has_results":false,"results_due":false,"sponsor_name":"Ipsen","sponsor_slug":"ipsen","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05795140","publication_url":"https://clinicaltrials.gov/study/NCT05795140","title":"A Multi-center, Single Arm, Open-label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Iptacopan in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Who Have Completed a Preceding Iptacopan Phase 3 Study in aHUS","has_exemption":false,"start_date":"2024-05-08","completion_date":"2032-07-16","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03033992","publication_url":"https://clinicaltrials.gov/study/NCT03033992","title":"Feasibility Trial of Optune for Children With Recurrent or Progressive Supratentorial High-Grade Glioma or Ependymoma, and Feasibility and Efficacy Trial of Optune in Conjunction With Radiation Therapy for Children With Newly Diagnosed DIPG","has_exemption":false,"start_date":"2017-04-04","completion_date":"2032-07-22","has_results":false,"results_due":false,"sponsor_name":"Children's Oncology Group","sponsor_slug":"childrens-oncology-group","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07634471","publication_url":"https://clinicaltrials.gov/study/NCT07634471","title":"A Phase 2/3 Randomized, Open-label Study of MK-1045 in Combination With Rituximab in Participants With 1L Follicular Lymphoma","has_exemption":false,"start_date":"2026-06-22","completion_date":"2032-07-23","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05112601","publication_url":"https://clinicaltrials.gov/study/NCT05112601","title":"A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma","has_exemption":false,"start_date":"2022-06-02","completion_date":"2032-07-30","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT02791581","publication_url":"https://clinicaltrials.gov/study/NCT02791581","title":"Understanding and Predicting Breast Cancer Events After Treatment (UPBEAT)","has_exemption":false,"start_date":"2017-07-21","completion_date":"2032-07-31","has_results":false,"results_due":false,"sponsor_name":"Wake Forest University Health Sciences","sponsor_slug":"wake-forest-university-health-sciences","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05952934","publication_url":"https://clinicaltrials.gov/study/NCT05952934","title":"A Phase II Clinical Trial of Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence","has_exemption":false,"start_date":"2024-02-12","completion_date":"2032-07-31","has_results":false,"results_due":false,"sponsor_name":"University of Arkansas","sponsor_slug":"university-of-arkansas","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07161544","publication_url":"https://clinicaltrials.gov/study/NCT07161544","title":"An Open-label, Multicenter, Two Part, Ascending Dose Followed by a Controlled Trial to Assess the Safety and Efficacy of a Subretinal Administration of AAVB-039 in Participants With Stargardt Disease (STGD1) (CELESTE)","has_exemption":false,"start_date":"2025-09-29","completion_date":"2032-07-31","has_results":false,"results_due":false,"sponsor_name":"AAVantgarde Bio Srl","sponsor_slug":"aavantgarde-bio-srl","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07355205","publication_url":"https://clinicaltrials.gov/study/NCT07355205","title":"A Phase Ib/II, Single-Center, Open-Label Study of First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (FLINN)","has_exemption":false,"start_date":"2026-07-07","completion_date":"2032-07-31","has_results":false,"results_due":false,"sponsor_name":"Washington University School of Medicine","sponsor_slug":"washington-university-school-of-medicine","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07876804","publication_url":"https://clinicaltrials.gov/study/NCT07876804","title":"A Long-term Study of Young Boys With X-linked Myotubular Myopathy Who Had Previously Received ASP2957","has_exemption":false,"start_date":"2026-10-31","completion_date":"2032-07-31","has_results":false,"results_due":false,"sponsor_name":"Astellas Gene Therapies","sponsor_slug":"astellas-gene-therapies","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07190300","publication_url":"https://clinicaltrials.gov/study/NCT07190300","title":"TulmiSTAR-02: A Two-part Phase I Dose Escalation Study of Tulmimetostat (DZR123) in Combination With Darolutamide or Abiraterone Followed by Open-label, Randomized, Phase II Dose Expansion Study to Assess the Safety and Efficacy of Tulmimetostat in Combination With Darolutamide Versus Darolutamide Alone in Patients With Metastatic Hormone-sensitive Prostate Cancer","has_exemption":false,"start_date":"2026-01-13","completion_date":"2032-08-02","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07567469","publication_url":"https://clinicaltrials.gov/study/NCT07567469","title":"A Phase 1/2 Open-Label, Safety and Efficacy Study of Neoadjuvant Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) and Cemiplimab Alone Followed by Adjuvant Fianlimab in Combination With Cemiplimab in Pediatric and Young Adult Participants With Recurrent or Progressive High-Grade Glioma or Pediatric and Adult Participants With Recurrent or Progressive Posterior Fossa-A Ependymoma","has_exemption":false,"start_date":"2026-08-31","completion_date":"2032-08-27","has_results":false,"results_due":false,"sponsor_name":"Regeneron Pharmaceuticals","sponsor_slug":"regeneron-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03579901","publication_url":"https://clinicaltrials.gov/study/NCT03579901","title":"Study of the Safety and Effectiveness of the Motiva Implants® Silicone Gel-Filled Breast Implants SmoothSilk® in Subjects Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction, and Revision Surgery","has_exemption":false,"start_date":"2018-04-06","completion_date":"2032-08-30","has_results":false,"results_due":false,"sponsor_name":"Motiva USA LLC","sponsor_slug":"motiva-usa-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07585266","publication_url":"https://clinicaltrials.gov/study/NCT07585266","title":"A Phase 3, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) Versus Imatinib in Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)","has_exemption":false,"start_date":"2026-07-27","completion_date":"2032-08-30","has_results":false,"results_due":false,"sponsor_name":"GlaxoSmithKline","sponsor_slug":"glaxosmithkline","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07550517","publication_url":"https://clinicaltrials.gov/study/NCT07550517","title":"A Phase II Non-blinded Randomized Study Comparing External Beam Radiotherapy (EBRT), 177Lu-PSMA-617, and Short Term Androgen Deprivation Therapy (ADT) Versus EBRT and Long Term ADT in Men With High Risk Localized Prostate Cancer","has_exemption":false,"start_date":"2026-08-17","completion_date":"2032-08-31","has_results":false,"results_due":false,"sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","sponsor_slug":"sidney-kimmel-comprehensive-cancer-center-at-johns-hopkins","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07766187","publication_url":"https://clinicaltrials.gov/study/NCT07766187","title":"Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma (CODAH Trial)","has_exemption":false,"start_date":"2026-10-31","completion_date":"2032-08-31","has_results":false,"results_due":false,"sponsor_name":"University of Wisconsin, Madison","sponsor_slug":"university-of-wisconsin-madison","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07645326","publication_url":"https://clinicaltrials.gov/study/NCT07645326","title":"A Pragmatic Phase 2 Trial of Risk-Adapted Treatment Approaches Including Treatment De-escalation to Minimize Adverse Effects of Hormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.","has_exemption":false,"start_date":"2026-12-31","completion_date":"2032-08-31","has_results":false,"results_due":false,"sponsor_name":"Georgetown University","sponsor_slug":"georgetown-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07219199","publication_url":"https://clinicaltrials.gov/study/NCT07219199","title":"Intraoperative Quantification of Residual IDH1-mutant Tumor Cells Via Ultra-Rapid Droplet Digital PCR","has_exemption":false,"start_date":"2027-08-31","completion_date":"2032-08-31","has_results":false,"results_due":false,"sponsor_name":"NYU Langone Health","sponsor_slug":"nyu-langone-health","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05496959","publication_url":"https://clinicaltrials.gov/study/NCT05496959","title":"177-Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (Lunar)","has_exemption":false,"start_date":"2022-09-02","completion_date":"2032-09-01","has_results":false,"results_due":false,"sponsor_name":"Jonsson Comprehensive Cancer Center","sponsor_slug":"jonsson-comprehensive-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04665739","publication_url":"https://clinicaltrials.gov/study/NCT04665739","title":"Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors","has_exemption":false,"start_date":"2023-02-03","completion_date":"2032-09-01","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06991335","publication_url":"https://clinicaltrials.gov/study/NCT06991335","title":"Deep Brain Stimulation (DBS) of the Ventral Capsule Ventral Striatum (VC/VS) for the Treatment of Apathy in Parkinson's Disease (PD)","has_exemption":false,"start_date":"2025-09-01","completion_date":"2032-09-01","has_results":false,"results_due":false,"sponsor_name":"Nora Vanegas","sponsor_slug":"nora-vanegas","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07683026","publication_url":"https://clinicaltrials.gov/study/NCT07683026","title":"Adaptive Platform Trial to Delay Progression From Normoglycemia to Dysglycemia in Presymptomatic Type 1 Diabetes: Golimumab Substudy","has_exemption":false,"start_date":"2026-08-08","completion_date":"2032-09-01","has_results":false,"results_due":false,"sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","sponsor_slug":"national-institute-of-diabetes-and-digestive-and-kidney-diseases-niddk","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07717411","publication_url":"https://clinicaltrials.gov/study/NCT07717411","title":"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease","has_exemption":false,"start_date":"2026-11-30","completion_date":"2032-09-03","has_results":false,"results_due":false,"sponsor_name":"Hoffmann-La Roche","sponsor_slug":"hoffmann-la-roche","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06136559","publication_url":"https://clinicaltrials.gov/study/NCT06136559","title":"A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011)","has_exemption":false,"start_date":"2023-12-13","completion_date":"2032-09-07","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04589845","publication_url":"https://clinicaltrials.gov/study/NCT04589845","title":"Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial","has_exemption":false,"start_date":"2021-01-18","completion_date":"2032-09-25","has_results":false,"results_due":false,"sponsor_name":"Hoffmann-La Roche","sponsor_slug":"hoffmann-la-roche","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT02984761","publication_url":"https://clinicaltrials.gov/study/NCT02984761","title":"CSP #2005 - Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy Trial (VALOR)","has_exemption":false,"start_date":"2017-04-13","completion_date":"2032-09-30","has_results":false,"results_due":false,"sponsor_name":"VA Office of Research and Development","sponsor_slug":"va-office-of-research-and-development","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04071457","publication_url":"https://clinicaltrials.gov/study/NCT04071457","title":"S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)","has_exemption":false,"start_date":"2019-08-13","completion_date":"2032-09-30","has_results":false,"results_due":false,"sponsor_name":"SWOG Cancer Research Network","sponsor_slug":"swog-cancer-research-network","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04687020","publication_url":"https://clinicaltrials.gov/study/NCT04687020","title":"Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)","has_exemption":false,"start_date":"2021-06-10","completion_date":"2032-09-30","has_results":false,"results_due":false,"sponsor_name":"NS Pharma, Inc.","sponsor_slug":"ns-pharma-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04910685","publication_url":"https://clinicaltrials.gov/study/NCT04910685","title":"A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis","has_exemption":false,"start_date":"2021-11-30","completion_date":"2032-09-30","has_results":false,"results_due":false,"sponsor_name":"Blueprint Medicines Corporation","sponsor_slug":"blueprint-medicines-corporation","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06475742","publication_url":"https://clinicaltrials.gov/study/NCT06475742","title":"A Phase 3, Multicenter, Open-label, Single-arm, Extension Study to Evaluate the Long-term Safety and Tolerability of Cenerimod in Adult Subjects With Moderate-to-Severe Systemic Lupus Erythematosus (SLE) on Top of Background Therapy","has_exemption":false,"start_date":"2024-07-30","completion_date":"2032-09-30","has_results":false,"results_due":false,"sponsor_name":"Viatris Innovation GmbH","sponsor_slug":"viatris-innovation-gmbh","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06574126","publication_url":"https://clinicaltrials.gov/study/NCT06574126","title":"Phase II Open-Label, Single Arm, Multicenter Study of Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma (GEM-CAR-HiRiSMM)","has_exemption":false,"start_date":"2024-09-30","completion_date":"2032-09-30","has_results":false,"results_due":false,"sponsor_name":"PETHEMA Foundation","sponsor_slug":"pethema-foundation","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06651970","publication_url":"https://clinicaltrials.gov/study/NCT06651970","title":"A Multicentre, Open-label, Randomised Phase IV Study to Investigate Acalabrutinib Monotherapy Compared to Investigator's Choice of Treatment in Adults (> 18 Years) With Chronic Lymphocytic Leukaemia and Moderate to Severe Cardiac Impairment","has_exemption":false,"start_date":"2025-02-04","completion_date":"2032-09-30","has_results":false,"results_due":false,"sponsor_name":"AstraZeneca","sponsor_slug":"astrazeneca","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07674901","publication_url":"https://clinicaltrials.gov/study/NCT07674901","title":"A Superiority Randomized Controlled Trial of Daily Knee Sleeve Use Versus No Use in Older Adults With Chronic Knee Pain","has_exemption":false,"start_date":"2026-09-30","completion_date":"2032-09-30","has_results":false,"results_due":false,"sponsor_name":"Margaret L Gourlay, MD, MPH","sponsor_slug":"margaret-l-gourlay-md-mph","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05563948","publication_url":"https://clinicaltrials.gov/study/NCT05563948","title":"Repeated Administration of Cannabis Varying in THC and CBD: Effects on Abuse Liability, Experimental Pain and Plasma Endocannabinoids","has_exemption":false,"start_date":"2026-10-01","completion_date":"2032-09-30","has_results":false,"results_due":false,"sponsor_name":"New York State Psychiatric Institute","sponsor_slug":"new-york-state-psychiatric-institute","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07388524","publication_url":"https://clinicaltrials.gov/study/NCT07388524","title":"Evaluating Adjuvant Atezolizumab or Atezolizumab and Hyaluronidase-TQJS to Prevent Recurrence in Stage I Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase III Trial (AASI-NSCLC)","has_exemption":false,"start_date":"2027-03-02","completion_date":"2032-09-30","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05460000","publication_url":"https://clinicaltrials.gov/study/NCT05460000","title":"A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy (N-Plus)","has_exemption":false,"start_date":"2024-10-11","completion_date":"2032-10-01","has_results":false,"results_due":false,"sponsor_name":"North Eastern German Society of Gynaecological Oncology","sponsor_slug":"north-eastern-german-society-of-gynaecological-oncology","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06953778","publication_url":"https://clinicaltrials.gov/study/NCT06953778","title":"CSP #2037S - Veterans Affairs Learning Health System Initiative to Assess Novel Screening vs. Usual Care and Treatment With Apixaban vs. Rivaroxaban in Veterans With Atrial Fibrillation (VALIANT-AF-S) Trial","has_exemption":false,"start_date":"2027-03-08","completion_date":"2032-10-01","has_results":false,"results_due":false,"sponsor_name":"VA Office of Research and Development","sponsor_slug":"va-office-of-research-and-development","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06953726","publication_url":"https://clinicaltrials.gov/study/NCT06953726","title":"CSP #2037T - Veterans Affairs Learning Health System Initiative to Assess Novel Screening vs. Usual Care and Treatment With Apixaban vs. Rivaroxaban in Veterans With Atrial Fibrillation (VALIANT-AF-T) Trial","has_exemption":false,"start_date":"2026-06-01","completion_date":"2032-10-04","has_results":false,"results_due":false,"sponsor_name":"VA Office of Research and Development","sponsor_slug":"va-office-of-research-and-development","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05212246","publication_url":"https://clinicaltrials.gov/study/NCT05212246","title":"CSP #2019 - Basal Cell Carcinoma Chemoprevention Trial (B3C)","has_exemption":false,"start_date":"2026-10-06","completion_date":"2032-10-06","has_results":false,"results_due":false,"sponsor_name":"VA Office of Research and Development","sponsor_slug":"va-office-of-research-and-development","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04576130","publication_url":"https://clinicaltrials.gov/study/NCT04576130","title":"A Danish Study to Assess the Efficacy of Implantable Cardioverter Defibrillator in Patients with Coronary Artery Disease Resuscitated from Ventricular Fibrillation Who Receive Complete Revascularization","has_exemption":false,"start_date":"2020-10-12","completion_date":"2032-10-31","has_results":false,"results_due":false,"sponsor_name":"Copenhagen University Hospital, Rigshospitalet","sponsor_slug":"copenhagen-university-hospital-rigshospitalet","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05508009","publication_url":"https://clinicaltrials.gov/study/NCT05508009","title":"Phase 1b/2a Trial of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) From an HLA-partially Matched Related or Unrelated Donor After TCRαβ+ T-cell/CD19+ B-cell Depletion for Patients Who Will Receive a Kidney Transplant (KT) From the Same HSCT/KT Donor","has_exemption":false,"start_date":"2023-01-10","completion_date":"2032-10-31","has_results":false,"results_due":false,"sponsor_name":"Alice Bertaina","sponsor_slug":"alice-bertaina","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06235697","publication_url":"https://clinicaltrials.gov/study/NCT06235697","title":"Androgen Suppression Combined With Elective Nodal Irradiation and Dose Escalated Prostate Treatment: A Non-Inferiority, Phase III Randomized Controlled Trial of Stereotactic Body Radiation Therapy Versus Brachytherapy Boost in Patients With Unfavourable Risk Localized Prostate Cancer","has_exemption":false,"start_date":"2024-04-25","completion_date":"2032-10-31","has_results":false,"results_due":false,"sponsor_name":"Canadian Cancer Trials Group","sponsor_slug":"canadian-cancer-trials-group","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06915025","publication_url":"https://clinicaltrials.gov/study/NCT06915025","title":"A Randomized Phase 3 Trial Evaluating the Safety & Efficacy of IP IMNN-001 Administered in Combination w/ Standard Neoadjuvant & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer","has_exemption":false,"start_date":"2025-07-09","completion_date":"2032-10-31","has_results":false,"results_due":false,"sponsor_name":"Imunon","sponsor_slug":"imunon","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07866430","publication_url":"https://clinicaltrials.gov/study/NCT07866430","title":"De-EscaLaTion of Aromatase Inhibitor Therapy: A Randomized Phase II Study of De-escalated Letrozole in Hormone Receptor-Positive Early Breast Cancer (DELTA Trial)","has_exemption":false,"start_date":"2026-09-30","completion_date":"2032-10-31","has_results":false,"results_due":false,"sponsor_name":"Montefiore Medical Center","sponsor_slug":"montefiore-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07867002","publication_url":"https://clinicaltrials.gov/study/NCT07867002","title":"Assessing Survival Outcomes With Checkpoint Inhibition ExteNded vs Discontinued in Endometrial Cancer","has_exemption":false,"start_date":"2026-10-31","completion_date":"2032-10-31","has_results":false,"results_due":false,"sponsor_name":"UNC Lineberger Comprehensive Cancer Center","sponsor_slug":"unc-lineberger-comprehensive-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07752875","publication_url":"https://clinicaltrials.gov/study/NCT07752875","title":"A Phase 1/2, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation","has_exemption":false,"start_date":"2026-12-01","completion_date":"2032-10-31","has_results":false,"results_due":false,"sponsor_name":"LG Chem","sponsor_slug":"lg-chem","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07880951","publication_url":"https://clinicaltrials.gov/study/NCT07880951","title":"Pediatric Randomized Trial Of Amino Acid Therapy Evaluating the Incidence of New Onset AKI","has_exemption":false,"start_date":"2027-10-31","completion_date":"2032-10-31","has_results":false,"results_due":false,"sponsor_name":"Children's Hospital Medical Center, Cincinnati","sponsor_slug":"childrens-hospital-medical-center-cincinnati","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07754292","publication_url":"https://clinicaltrials.gov/study/NCT07754292","title":"Off-Label Treatment With Immune Checkpoint Inhibitor Blockade","has_exemption":false,"start_date":"2026-11-01","completion_date":"2032-11-01","has_results":false,"results_due":false,"sponsor_name":"Medical College of Wisconsin","sponsor_slug":"medical-college-of-wisconsin","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07605416","publication_url":"https://clinicaltrials.gov/study/NCT07605416","title":"Quadruplet Induction Followed by Teclistamab Consolidation and Doublet Maintenance in Patients With Primary Plasma Cell Leukemia: The QUANTUM Trial","has_exemption":false,"start_date":"2027-04-20","completion_date":"2032-11-06","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04924075","publication_url":"https://clinicaltrials.gov/study/NCT04924075","title":"A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations","has_exemption":false,"start_date":"2021-08-12","completion_date":"2032-11-18","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03897881","publication_url":"https://clinicaltrials.gov/study/NCT03897881","title":"A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (KEYNOTE- 942)","has_exemption":false,"start_date":"2019-07-18","completion_date":"2032-11-21","has_results":false,"results_due":false,"sponsor_name":"ModernaTX, Inc.","sponsor_slug":"modernatx-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07872046","publication_url":"https://clinicaltrials.gov/study/NCT07872046","title":"A Phase 3a Observer-blind, Randomized, Placebo-controlled, Multi-country Study to Evaluate the Impact of Recombinant Zoster Vaccine on Major Adverse Cardiovascular Events in Adults >=50 Years of Age With Established Cardiovascular Disease or With >=2 Cardiovascular Risk Factors","has_exemption":false,"start_date":"2026-11-30","completion_date":"2032-11-25","has_results":false,"results_due":false,"sponsor_name":"GlaxoSmithKline","sponsor_slug":"glaxosmithkline","status":"ongoing","is_pact":false,"days_late":null}]}